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ABSTRACT 
 
Equine pituitary pars intermedia dysfunction (PPID) is a common endocrine disease of the older 
horse. First described in 1932, and likened to human Cushing’s disease, it is associated with an 
enlargement of the pituitary gland that was classically termed an adenoma. The underlying 
mechanism is attributable to a lack of dopaminergic inhibition of the pars intermedia. Treatment 
methods have remained essentially unchanged for 30 years and the prevalence data have mainly 
stemmed from Eastern Australia and the USA. The general objective of this thesis was to explore 
the feasibility of developing a targeted cell-specific approach for the treatment of equine PPID. 
The specific aims were to confirm the need for this advanced therapy by determining the 
prevalence of PPID in horses globally; to continue the investigation of the underlying cellular 
mechanism of PPID by confirming the role of pro-hormone convertases, and sequence the equine 
pro-opiomelanocortin, prohormone convertase 1 and 2 genes; and to investigate the methodology 
for site-specific applications of future therapy for equine PPID. These aims were met by 
reporting the prevalence data from a worldwide audience of veterinarians using an internet-based 
survey tool; by describing partial gene sequences of the equine proopiomelanocortin and 
prohormone convertase enzymes and their expression in normal and PPID horses; and by 
showing how low-volume contrast enhancement of the brain using computed tomography can 
delineate the margins of the pituitary gland, showing how general anesthesia effects the pulsitility 
and concentration of adrenocorticotrophic hormone, and finally, modifying a previously reported 
technique, by developing a novel surgical approach to the treatment of this classical condition. 
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CHAPTER 1 
 
LITERATURE REVIEW 
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1.1 INTRODUCTION 
 
Equine pituitary pars intermedia dysfunction (PPID), also known as equine Cushing’s disease, 
was first described in 1932 (Pallaske 1932). It is a common endocrine disease of older horses, 
frequently co-diagnosed with equine metabolic syndrome (EMS; Donaldson et al. 2004; 
Karikoski et al. 2011; Ireland et al. 2013; Welsh 2016). Clinical signs are typically noted in 
horses older than 15 years and are rare in horses under 10 years old (Orth et al. 1982; Schott 
2002). 
 
The reported prevalence of disease is varied and depends greatly on the population of horses, and 
the methods used to diagnose the condition (Table 1.1). It varies from 0.025% of all horses in a 
hospital population, to 39% in a study that focused on a small number of aged horses. There does 
not appear to be a sex predisposition, despite early reports to the contrary (McFarlane 2011). This 
difference may reflect the fact that female horses could have been kept to an older age due to 
their breeding potential, whereas castrated males (geldings) may have been euthanased at an 
earlier age, confounding the sex-effect. Ponies and Morgan horses were thought to be 
predisposed to the development of PPID (McFarlane 2011). However, an Australian study of 340 
aged horses (McGowan 2013) found that while ponies were older, there was not a breed or height 
significance associated with the diagnosis of PPID. Additionally, the disease has been reported in 
other equid species, such as donkeys and onagers (Peel et al. 2009). 
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Table 1.1 Reported prevalence of equine pituitary pars intermedia dysfunction. 
First Author Publication 
Year 
Case Definition Population 
(Study Duration) 
N Age 
(Years) 
Location Prevalence 
(%) 
Evans 1972 Not stated Practice 4000 All ages USA 
0.075 - 0.15 
Estimated 
van der Kolk 1993 
Hirsutism and endogenous 
ACTH 
Hospital 
(1 year) 
1800 All ages Netherlands 0.5 
Mellor 2001 Not stated 
Owner 
Questionnaire 
1230 All ages UK < 1 
Chandler 2001 
Clinical examination and 
DST 
Hospital 
(4 months) 
23 26.5 (median) UK 39 
Brosnahan 2003a 
Hirsutism or endogenous 
ACTH or Necropsy 
 
Hospital 
(10 Years) 
 
467 
All horses 
> 20 
> 30 
USA 
0.36 
10 
19 
Brosnahan 2003b Veterinarian Diagnosed 
Owner 
Questionnaire 
218 > 20 USA 8 
Ireland 2011 
Shedding / moulting changes 
“Cushing’s Syndrome” 
Owner 
Questionnaire 
918 > 15 UK 
12.5 
3.3 
Rohrbach 2012 
Hirsutism 
DST 
DST / TRH stimulation 
 
Hospital 
11 Years 
1993 
2002 
134,632 All ages USA 
0.16 
 
0.025 
0.37 
Ireland 2013 Not stated 
Owner 
Questionnaire 
797 All ages UK 2.8 
McGowan 2013 Hair coat changes 
Owner 
Questionnaire 
339 > 15 Australia 14 
McGowan 2013 Endogenous ACTH Test 
Horses from 
above study 
325 > 15 Australia 21.2 
Welsh 2016 Not stated 
Multi-hospital 
Records 
26 Years 
70477 All ages UK 2.9 
3
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Cushing’s disease in canine and human patients can be either pituitary-dependent or pituitary-
independent depending on the source of the endocrine abnormality. In the former case there is an 
over secretion of adrenocorticotrophic hormone (ACTH) by a benign, but functional, adenoma of  
the pars distalis of the pituitary gland. This acts on the adrenal glands and stimulates an over 
secretion of cortisol. The resultant clinical signs and homeostatic disturbances are a result of this 
elevated serum cortisol. In pituitary independent Cushing’s disease, the abnormality resides 
wholly within the adrenal glands with the same resultant effects. Equine Cushing’s disease, or 
PPID, differs from both of the aforementioned conditions in that while it is almost exclusively 
the result of hyperplasia and hypertrophy of the pars intermedia of the pituitary gland, the 
resulting hormonal disturbance is a result of increased circulating levels of proopiomelanocortin 
(POMC) peptides with only a minority of horses having adrenal hyperplasia and increased 
circulating serum cortisol.  
 
1.2 ANATOMY 
 
The pituitary gland lies within a bony depression (the sella turcica) of the basisphenoid bone at 
the base of the cranium. It is dorsoventrally flattened (along the long-axis) in the horse such that 
it lies almost parallel to the hypothalamic base in the midbrain. Separated from the rest of the 
brain by a thick fold of dura mater (the diaphragma sella) there is a foramen through which the 
infundibular stalk is attached to the hypothalamus. 
 
There are 2 major divisions of the pituitary gland associated with its embryological development. 
The anterior pituitary, or the adenohypophysis, originates from an invagination of the pharyngeal 
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epithelium, called Rathke’s pouch. It is comprised of 3 lobes, the pars distalis, the pars tuberalis 
and the pars intermedia. The posterior pituitary, or neurohypophysis, is composed of the pars 
nervosa, an outgrowth of neural tissue from the hypothalamus (Hall 2011). The pars nervosa is 
comprised of axons and nerve terminals originating in the paraventricular and supraoptic nuclei 
of the hypothalamus which stores and releases hormones oxytocin and arginine vasopressin (also 
known as anti-diuretic hormone). 
 
The pars distalis is comprised of corticotrophs (producing ACTH); somatotrophs (growth 
hormone); lactotrophs (prolactin); thyrotrophs (thyroid stimulating hormone) and gonadotrophs 
(lutenising hormone and follicular stimulating hormone). The pars tuberalis, which surrounds the 
infundibular stalk, contains cells expressing melatonin receptors on their surface, the relative 
density of which changes in relation to daylight length. These bind melatonin produced by the 
pineal gland under the direction of the suprachiasmatic nucleus of the hypothalamus which, in 
turn, is influenced by the retinohypothalamic tract from the retinal ganglion cells. The cells 
subsequently regulate the production and release of reproductive hormones from the pars distalis 
(Masson-Pevet et al. 1994; Revel et al. 2009). The melanotrophs are the sole endocrine cell of 
the pars intermedia (McFarlane 2011). These produce α-melanocyte stimulating hormone 
(αMSH), β-endorphin, ACTH, corticotropin-like intermediate hormone (CLIP), and other POMC 
peptides, all of which are derived from POMC.  
 
The vascular anatomy of the equine hypophysis, excluding the pars intermedia, has been 
described in depth (Vitums 1975). The internal carotid artery gives rise to the rostroventral 
infundibular (hyophyseal) arteries supplying the ventral capillary network of the median 
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eminence of the hypothalamus. Ventral and dorsal hypophyseal vessels descend through the pars 
tuberalis to supply blood to the distal part of the adenohypophysis terminating in the sinusoidal 
network of the pars distalis. The right and left caudal infundibular arteries arise from the caudal 
intercarotid artery (and in some cases the internal carotid artery) and, running in a sheath of dura 
mater, pass through the intercavernous sinus to become a capillary network in the most distal 
aspect of the pars nervosa (and infundibular stalk). 
 
Venous drainage is caudal to the left and right cavernous sinuses. There are 2 paths, 
caudoventrally into the ventral petrosal sinus and foramen lacerum and, secondly, rostrolaterally 
exiting via the orbital fissure into the ophthalmic vein and then the deep facial vein (Vitums 
1978). The latter course gives rise to an exquisite method of assessing equine hypophyseal 
hormone production (Irvine et al. 1984; Irvine et al. 1987; Alexander et al. 1996).  
 
1.3 PHYSIOLOGY 
 
The physiology of the hypophysis is controlled by the hypothalamus. There are a number of 
hypothalamic releasing and inhibiting hormones produced in a myriad nuclei (Hurcombe 2011). 
The corticotrophs (producing POMC and subsequently, ACTH) are stimulated by corticotrophin-
releasing hormone produced in the parvocellular neurons in the paraventricular nucleus of the 
hypothalamus. The somatotrophs (producing growth hormone) are stimulated by growth 
hormone-releasing hormone produced in the arcuate nucleus and thyrotrophin releasing hormone 
(TRH) from the paraventricular nucleus of the hypothalamus. The latter hormone also stimulates 
the corticotrophs. Negative feedback results in the production of somatostatin (also known as 
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GH-inhibiting hormone) in the hypothalamus. The lactotrophs (producing prolactin) are 
stimulated by TRH and inhibited by dopamine produced in the tuberoinfundibular neurons of the 
arcuate nucleus of the hypothalamus (Hurcombe 2011). The thyrotrophs (producing thyroid 
stimulating hormone) are stimulated by TRH. The gonadotrophs (producing luteinising hormone 
and follicular stimulating hormone) are stimulated by gonadotrophin-releasing hormone 
produced in the preoptic nucleus of the hypothalamus. 
 
In contrast, the melanotrophs of the pars intermedia are stimulated by TRH (as above) promoting 
the synthesis and secretion of POMC and the derived peptides. Melanotrophs are under the tonic, 
inhibitory control of dopamine secreted by dopaminergic neurons located in the periventricular 
nucleus of the hypothalamus. The axons transit the infundibular stalk, terminating on the 
melanotrophs, releasing the dopamine to bind to type-2 dopamine receptors (D2R) in the pars 
intermedia. 
 
POMC produced by both the corticotrophs of the pars distalis and the melanotrophs of the pars 
intermedia undergoes further modification by 2 distinct pro-hormone convertase enzymes, PC1 
and PC2, under dopaminergic control. PC1 is expressed in both melanotrophs and corticotrophs 
of the pars intermedia, where POMC is converted to ACTH.  PC2, which converts ACTH to 
αMSH and CLIP, is expressed in the melanotrophs alone. In the unaffected horse (non-PPID) the 
presence of PC2 in the melanotrophs will modify any ACTH produced by PC1 (from POMC) 
into αMSH and CLIP. Therefore, the majority of ACTH in normal horses will be a product of the 
pars distalis and αMSH and CLIP will be products of the pars intermedia (Wilson et al. 1982). 
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1.4 PATHOPHYSIOLOGY 
 
The underlying etiology of equine PPID is a specific expansion of the melanotrophs of the pars 
intermedia of the pituitary gland (McFarlane et al. 2005). These changes have been variably 
reported as hyperplasia, hypertrophy and classically, as a neoplasm in the form of an adenoma.  
 
Melanotrophic expansion could occur as a result of over stimulation with TRH, or a lack of 
dopaminergic inhibition. Hypothalamic TRH stimulates multiple cell lines in the pars distalis as 
well as the melanotrophs of the pars intermedia and, so, hypersecretion of TRH should result in 
multiclonal expansion; however, this does not occur (Korbonits et al. 2004). TRH from the 
paraventricular nucleus is released into the blood vessels of the median eminence to bind to its 
cellular targets in the pars distalis (Hurcombe 2011). In contrast, the mechanism by which TRH 
reaches the melanotrophs, in the relatively poorly vascularized pars intermedia is unknown. It is, 
therefore, theoretically possible that this difference in delivery mechanism could result in 
monoclonal expansion of the melanotrophs.  
 
A lack of dopamine inhibition could also result in multiclonal expansion. However, as the 
dopamine producing neuronal cell bodies of the lactotrophs are located in the arcuate nucleus and 
those of the melanotrophs are in the periventricular nucleus, a highly specific regional loss of 
these dopamine producing cells may explain the monoclonal expansion of the melanotrophs. 
Indeed, there is now good evidence that PPID is a neurodegenerative disorder characterized by a 
lack of dopaminergic input to the melanotrophs of the pars intermedia (McFarlane 2007). 
Abnormalities in both the absolute and relative abundance of POMC-derived peptides normalize 
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in the presence of the dopamine agonist, pergolide mesylate, resulting in subsequent 
improvement in clinical signs and diagnostic test results of PPID affected horses (Orth et al. 
1982). Tissue from the pars intermedia of PPID horses has been reported to contain 8 times less 
dopamine, and 6-times less dopaminergic nerve terminals than that from aged-matched controls 
(Millington et al. 1998). Additionally, the periventricular nucleus of the hypothalamus in PPID 
horses contains 50% less dopaminergic neuronal cell bodies than age-matched control horses 
(McFarlane et al. 2005). These findings complement earlier cell culture research suggesting that 
POMC mRNA expression and the amount of immunoreactive β-endorphin was reduced in the 
face of a specific D2R agonist (quinpirole; Gehlert et al. 1988). Additionally, in a sheep model 
using hypothalamic-pituitary disconnected ewes, researchers found that without hypothalamic 
input, plasma levels of ACTH and cortisol rose. This led them to conclude that there was some 
tonic inhibitory input from the hypothalamus which was removed in their disconnect sheep, 
compared to those with intact hypothalamic-pituitary axes (Engler et al. 1990). It is interesting to 
note that these researchers discounted dopamine as the inhibitory agent based on a lack of effect 
on basal or stimulated ACTH production. However, the researchers were applying the dopamine 
treatments to the anterior pituitary and not the intermediate pituitary in this experiment. 
Goudreau et al. (1992) disconnected the periventricular nucleus from the pituitary gland in a rat 
model and found that the levels of plasma αMSH increased. These same researchers electrically 
stimulated the periventricular nucleus of the hypothalamus in rats with intact hypothalamic-
pituitary axes and found that the plasma concentration of αMSH decreased. 
 
Studies in dopamine receptor deficient mice have resulted in the pituitary hyperplasia (Saiardi et 
al. 1997). Concurrently, PC upregulation occurs, however, PC1 increases in activity by 4 to 5 
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times whereas that of PC2 increases by only 2 to 3 times (Saiardi et al. 1998). This differential 
activity would result in an overabundance of ACTH and a relative failure of further conversion 
into the downstream products, i.e., αMSH and CLIP. 
 
The underlying mechanism for a lack of dopaminergic control is not known. However, there is a 
suggestion that oxidative stress plays a significant role. There is a significant increase in the 
amount of 3-nitrotyrosine (an oxidative stress marker) present in the periventricular nucleus of 
the hypothalamus in PPID horses compared to normal horses (McFarlane et al. 2005). 
Additionally, lipofuscin (a pigment associated with oxidized cell debris) has been found in the 
pars nervosa and the inter-septal tissues separating melanotroph clusters in the pars intermedia of 
PPID horses (Glover et al. 2009); both of these corresponding to the position of periventricular 
neurons from the hypothalamus (Saland 2001). Further, as has been found in human Parkinson’s 
disease patients, the amount of α-synuclein has been found to be increased in PPID horses, when 
compared to normal horses (McFarlane et al. 2005). α-synuclein is a natural protein that 
accumulates by either increased production or reduced clearance (misfolding and aggregation) 
causing cell death. 
 
There are 11 dopaminergic cell groups and 4 main pathways in the brain. So far, only the 
periventricular nuclear neuronal cell bodies have been reported to have been examined for a 
dopamine lack in the horse. Therefore, it is unknown whether PPID represents a dopaminergic 
defect solely of the periventricular nucleus or whether the other pathways are also affected. The 
substantia nigra has been examined (McFarlane, personal communication) and found to contain 
normal numbers of dopamine neuronal cell bodies. It is possible that the privileged position of 
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the pituitary gland (outside the blood-brain barrier) allows for the access of environmental toxins, 
or other agents, resulting in the selective destruction of the periventricular dopamine producing 
nuclei via the tuberoinfundibular pathway.   
 
Irrespective of the underlying etiology, the melanotrophic cell line expansion results in the 
overproduction and systemic release of POMC and its downstream peptides resulting in the 
myriad clinical signs associated with PPID in the horse. 
 
1.5 CLINICAL SIGNS 
 
Hirsutism (more correctly termed hypertrichosis, see below) is the most unique and frequent 
clinical sign in the horse occurring in 55% to 80% of horses with PPID. Horses typically present 
with long, shaggy, or curly, hair coats that have failed to shed normally after winter. Other early 
signs may include longer hair in the jugular groove or distal limbs. The pathogenesis of this 
abnormality is unknown, however, theories include an increased androgen secretion from adrenal 
tissue (as seen in women with human Cushing’s disease) and a dysfunction in thermoregulation 
at the level of the hypothalamus. While pituitary compression is cited, there is no evidence to 
support this theory. There is, however, evidence that age-related oxidative stress occurs in the 
hypothalamic-pituitary axis of rats (Kobayashi et al. 2009) and it is possible that the elevated 
levels of 3-nitrotyrosine (an oxidative stress marker) present in the periventricular nucleus of the 
hypothalamus in PPID horses, as noted by McFarlane (2005), have an unknown effect on the 
thermoregulatory mechanisms of this critical region of the brain. Yet another possibility is that 
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abnormal concentrations, or inappropriate temporal relationships between prolactin and other 
hormones may be responsible for hair retention in PPID (Thompson et al. 1997a and b). 
 
Irrespective of the pathogenesis, a recent publication (Innera et al. 2013) has reported that horses 
suffering from PPID did not have an increased total number of hair follicles in skin biopsy 
samples compared to age and sex-matched normal horses. Rather, the hirsutism was a function of 
a greater number of hair follicles in the resting stage, resulting in a failure to shed the hair shaft. 
This led the researchers to suggest that the term hirsute is not correctly applied to PPID horses 
and that hypertrichosis would be a more appropriate term. Older, hirsute horses are 5-times more 
likely to have a positive PPID test result than similarly aged animals without hair coat 
abnormalities (McGowan 2008). The positive predictive value (PPV) of this clinical sign in the 
diagnosis of the disease condition is heavily dependent on the prevalence of the condition in the 
population under examination. Frank et al. (2006) reported a PPV of 90% in a population of 
horses that had been selected for having hairy coats (PPID prevalence of 62%), whereas 
McGowan et al. (2013) reported a PPV of only 33% in an unselected population of horses 
subsequently determined to have PPID based on having elevations in seasonally-adjusted 
endogenous ACTH values. The prevalence of the condition in this population of horses was 
21.2%. Schott et al. (2017) reported on the reliability of a clinical scoring system for PPID. These 
researchers used 5 clinical signs (hypertrichosis, hyperhidrosis, polyuria and polydipsia, 
abnormal fat deposition and muscle wasting) in addition to an elevated basal ACTH 
concentration or an abnormal dexamethasone suppression test. The outcome of this study was 
that hypertrichosis was useful to differentiate between PPID and normal horses, but that a more 
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detailed scoring system needed more investigation. Other causes of hypertrichosis (or hirsutism) 
in the horse are rare. There are isolated case reports of iatrogenic adrenal insufficiency associated 
with anabolic steroid treatment (Dowling et al. 1993), a functioning adrenocortical tumor (van 
der Kolk et al. 2001), and a case of pituitary lymphoma (Mitsui 2007) that have been reported as 
causing abnormal hair coats or abnormal shedding profiles in horses. 
 
Chronic, recurrent laminitis has been reported in up to a third of PPID horses, even in the 
absence of hirsutism (Donaldson et al. 2004). The pathogenesis remains elusive. Recent studies 
have implicated elevated serum insulin concentrations (McGowan et al. 2003, 2013 and Carter et 
al. 2009) and an equine model of  supra-physiological doses of insulin in the face of normal 
insulin sensitivity and serum glucose concentration resulted in laminitis (Asplin et al. 2007; de 
Laat et al. 2010). De Laat et al. (2017) showed that the insulin levels in horses with pasture 
associated laminitis was higher in horses with concurrent PPID and equine metabolic syndrome 
(EMS), than with either PPID or EMS alone. Interestingly, in this group of horses, the serum 
insulin concentration was significantly positively correlated with the severity (Obel grade) of 
laminitis (Obel 1948). Finally, it would be disingenuous to consider laminitis and pathologies of 
the equine foot while excluding other collagen-type abnormalities occurring concurrently in 
PPID horses. Alterations in muscle mass, body weight and fat distribution under the influence of 
POMC-derived peptides or subsequent cortisol or androgen (Morgan et al. 2017) metabolism 
may fundamentally alter the basement membrane of the equine foot lamellae making it more 
prone to laminitic episodes. Indeed, a recent paper by Karikoski (2016) showed that horses with 
PPID had more sharp axial primary epidermal lamellae than control horses and horses with PPID 
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and concurrent EMS, for reasons that are unknown at this time. These authors also found that the 
degree of lamellar change was correlated with having PPID and hyperinsulinemia. This 
suggested that older horses could have concurrent PPID and EMS and that the laminitis 
associated with PPID may actually be a function of EMS and not PPID per se. 
The pathophysiology behind weight loss in PPID horses is unknown. This early clinical sign 
occurs in up to 88% of horses with PPID, but is sometimes absent. There are even low numbers 
of horses which have a normal body condition or that are obese (Hillyer et al. 1992; Schott 
2002). Fat redistribution, as evidenced by bulging supra-orbital fat pads, a “cresty” neck, tail 
head fat, as well as pre-mammary and preputial fat (Hillyer et al. 1992) occurs in between 15% 
and 30% of horses with PPID (McFarlane 2011). Typically, cases present with a pendulous 
abdomen and loss of epaxial musculature. Interestingly, muscle biopsies of these abnormal 
horses indicate histological changes consistent with glucocorticoid excess in other species (Tice 
et al. 1967; Pleasure et al. 1970; Aleman et al. 2006, 2010). The role, if any, of the POMC-
derived peptides in PPID-associated muscle atrophy or obesity has not been determined. Given 
that a significant proportion of PPID horses are now known to have concurrent EMS (30% are 
hyper-insulinemic; Donaldson et al. 2004; Karikoski et al. 2011; Ireland et al. 2013; Welsh 2016) 
the complex interrelationship between the disease conditions makes apportioning clinical signs 
difficult. 
 
Hyperhidrosis is commonly reported as a clinical sign in horses with PPID (Schott 2002). These 
animals are not typically hyperthermic and thus the sweating may be the result of the 
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hypertrichosis, in which case simply clipping the excess hair from the horse may result in 
resolution of this clinical sign. In other cases, compression of the hypothalamic thermal 
regulation center may account for the abnormality, however, this has not been determined. There 
are also cases of anhidrosis (lack of sweating) being reported in cases of PPID (McFarlane 2010). 
 
Polyuria and polydypsia has been inconsistently reported in PPID horses, occurring in between 
0% (van der Kolk et al. 1993) and 76% of horses (Hillyer et al. 1992). Overall, the incidence is 
approximately 30% (McFarlane 2011). Mechanisms postulated include reduced antidiuretic 
hormone secretion from the pars nervosa due to compression from the pars intermedia, an 
osmotic diuresis due to increased circulating levels of glucose, as well as an unknown effect of 
increased cortisol concentrations acting in the central nervous system.  
 
Docility, lethargy, and less commonly, decreased responsiveness to painful stimuli have been 
reported, which have been associated with an increase in the production of β-endorphin in PPID 
horses (Millington et al. 1988). Opportunistic infections associated with the skin, respiratory tract 
(including dental related sinusitis), and abscesses have been reported in 35% of horses with PPID 
as compared to 11% of healthy aged horses (McFarlane 2011). The mechanism of these findings 
is not fully elucidated, however, the increased concentration of a cocktail of immunosuppressive 
hormones including ACTH, β-endorphin, αMSH and cortisol associated with this problem makes 
a simple etiology unlikely. Interestingly, work by McFarlane et al. (2015) showed that neutrophil 
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function was reduced in PPID horses (decreased oxidative burst activity and adhesion) compared 
to control horses.  
 
Reproductive problems in aged PPID positive mares are reported to be multiple and include 
failure to cycle, or inappropriate cyclicity, endometritis, infertility, and inappropriate lactation 
(Love 1993; McCue 2002). This broad group of abnormalities is typically reported in review 
papers and the underlying mechanism(s) are unknown (Johnson et al. 2011). One suggestion is 
that compression of the pars distalis by the pars intermedia leads to a reduction in luteinizing 
hormone and follicular stimulating hormone secretion and altered cyclicity in PPID positive 
females (Linse 2011). There is only 1 case report of a mare fitting the clinical and 
clinicopathological profile of PPID being treated medically and then beginning to cycle normally 
(Panzani et al. 2003). Beyond this report, the current author can find no direct evidence of the 
effect of PPID on reproductive function in age and sex matched horses. 
 
1.6 DIAGNOSTIC TESTING 
1.6.1 HORMONE CONCENTRATIONS 
 
Definitive diagnosis of equine PPID is complicated as there is no unequivocal test. The disease 
process is slowly progressive such that by the time a diagnosis is attempted, the pathological 
changes within the hypophysis have likely been present for a significant period of time. 
Historically, the majority of clinicians were presented with a hypertrichotic horse which formed 
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the basis for the diagnosis. Subsequent to that, the evaluation of certain serum hormone 
concentrations could increase the likelihood of a definitive diagnosis, but there is no definitive 
antemortem test to which to refer. Recently, however, with the help of industry fundinga, the 
number of non-hypertrichotic horses being tested for PPID has increased dramatically in the UK, 
Europe and Australia.  
 
There is a distinct seasonality to the hormonal output of the equine pars intermedia, just as in 
other seasonal breeders. As such, plasma concentrations of the main POMC-derived peptides, 
αMSH and ACTH, are significantly elevated between August and October (possibly as early as 
July), autumn in the Northern Hemisphere (Logan et al. 1980; McFarlane et al. 2004; Donaldson 
et al. 2005; Beech et al. 2009; Lee et al. 2010; Frank et al. 2010; Place et al. 2010; Copas and 
Durham 2012). Similarly, Secombe et al. (2017) indicated that there was a day-length effect on 
endogenous basal ACTH production in the Southern Hemisphere (Australia) and that horses 
closer to the equator (Townsville, Queensland) had a higher basal level of ACTH with a reduced 
elevation between the summer solstice and autumn equinox (January to May), than horses further 
from the equator (Perth, Western Australia) who had a lower basal endogenous concentration but 
a greater elevation in the January to May period. These researchers suggested that the latitude 
difference was associated with reduced day length changes closer to the equator. The overall 
effect is that variations in seasonal endogenous basal ACTH concentrations can result in false-
positive diagnoses when diagnostic tests are performed without using seasonally adjusted 
reference ranges. 
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There are a variety of hormone-based tests used for the diagnosis of PPID. Historically, the most 
common was the dexamethasone suppression test (Dybdal et al. 1994) which was originally 
reported to have 100% sensitivity and 100% specificity. In the normal horse, ACTH from the 
pars distalis acts on the adrenal gland to release cortisol. An increase in the circulating 
concentration of cortisol then acts in negative feedback fashion to reduce the output of ACTH. 
Administration of dexamethasone (a corticosteroid-based hormone) in the normal horse will 
therefore result in a suppression of the basal cortisol level by reducing the production of ACTH. 
In the horse with PPID, the increased ACTH production is derived from the pars intermedia, not 
the pars distalis, and is not responsive to the negative feedback inhibition due to a receptor lack, 
rather than neoplastic autonomy (Antakly et al. 1984; Seger et al. 1988), and so cortisol 
suppression does not occur (cortisol greater than 1 μg/dL 19 hours after dexamethasone 
administration is suggestive of PPID). Additionally there is a concern amongst clients and 
veterinarians that using a corticosteroid (dexamethasone) will induce laminitis in these 
compromised animals and thus the dexamethasone suppression test has fallen out of favor. 
 
In horses with PPID, ACTH is produced in the pars intermedia as well as the pars distalis, and so, 
an increase in the basal level of this circulating hormone was reported as a simple, single test for 
PPID (Couëtil et al. 1996; Lee et al. 2010). McGowan et al. (2013) reported a sensitivity and 
specificity of 80% and 83%, respectively, for a single serum ACTH sample using a cut-off value 
of 29.7 pg/mL in seasons other than autumn. In autumn, using a cut-off value of 77.4 pg/mL the 
sensitivity improved to 100% with a specificity of 95%. An elevation in the basal plasma 
concentration of ACTH is currently recommended as a diagnostic test for PPID, on the caveat 
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that seasonally adjusted reference values (greater than 35 to 50 pg/mL, chemiluminescent or 
radioimmunoassay respectively; November to July) and greater than 100 pg/mL (August to 
October) are used (McFarlane 2011; Copas and Durham 2012). Most recently Durham (2017) 
suggested that these adjusted values may need further investigation as there appeared to be a 
lower level of endogenous basal ACTH concentration in horses in April, preceding the rise from 
July to November. Furthermore, it is important to note that there are significant differences in the 
values returned by different testing methodologies (chemiluminescent, immunofluorescent or 
radioimmunoassay; Irvine et al. 2016; Knowles et al. 2017), there may also be an age, sex, pony 
breed (Shetlands) and colour (grey) effect of having higher endogenous basal ACTH levels 
(Durham 2017). 
 
In contrast, irrespective of disease status, αMSH is produced solely in the pars intermedia. TRH 
stimulation of normal and PPID horses (McFarlane 2006) indicated that both normal and PPID 
horses had marked increases in αMSH after TRH stimulation. There was no significant 
difference in the magnitude of the response, although horses with PPID had higher αMSH levels 
both before and after stimulation. McGowan et al. (2013) reported using elevations in basal 
endogenous αMSH levels as a diagnostic test. This had a moderately good specificity and 
sensitivity of 93% and 59%, respectively, using a cut-off value of 52.0 pmol/L in seasons other 
than autumn. In autumn the specificity and sensitivity improved to 97% and 100% respectively, 
using a cut-off value of 165.4 pmol/L. In this paper, the definitive diagnosis was provided using 
hirsutism, in addition to 3 or more clinical signs of PPID.  
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The ACTH stimulation test is based upon the supposition that in the face of an increased 
concentration of circulating ACTH, an abnormally enlarged (or primed) adrenal gland will 
respond by increasing the output of cortisol to be measured in the serum. Unsurprisingly, as 
adrenal gland hyperplasia in horses with PPID is uncommon (McFarlane 2011), and ACTH 
concentration is affected by a multitude of factors (Nagata et al. 1999; Fazio et al. 2008), 
conflicting results have been reported (Hillyer et al. 1992; Dybdal et al.1994; van der Kolk et al. 
1995).  
 
As described above, melanotrophs of the pars intermedia of the pituitary are stimulated by TRH 
produced in the hypothalamus. This positive effect is retained in PPID and is the basis behind the 
TRH-stimulation test, which originally measured the increase in serum cortisol produced as a 
result of exogenously administered TRH (Beech et al. 1985). However, non-diseased animals 
also have a response to TRH stimulation, and 10 of 16 animals had greater than 30% increase in 
serum cortisol (McFarlane et al. 2006). To circumvent this problem, Beech et al. (2007) reported 
measuring serum concentration of ACTH after TRH stimulation (1 mg intravenously), instead of 
cortisol, and used cut-off values of 100 pg/mL and 35 pg/mL measured 10 minutes and 30 
minutes after TRH injection. This test is currently advocated in cases where an equivocal 
endogenous basal ACTH concentration has been measured. The current recommendation is that 1 
mg of TRH is administered and blood drawn for the determination of ACTH concentration 
before administration and at 10 and 30 minutes after administration. Cut-off values are reported 
to be greater than 110 pg/mL at 10 minutes, and greater than  65 pg/mL at 30 minutes after 
stimulation, however, both Goodale et al. (2013) and Funk et al. (2011), reported that further 
studies were required to determine cut-off values. A recent Australian paper (Byrne et al. 2017) 
 21  
reported the high variability of autumnal TRH stimulation test results in normal horses in 
Australia, noting that there was considerable overlap between PPID and non-PPID affected 
horses. Adams et al. (2017) evaluated the seasonal effect of ACTH response to TRH stimulation 
and noted a sensitivity and specificity of 86% and 92%, respectively, in the autumn months, with 
a cut-off of 480 pg/mL. In the non-autumn months a cut-off of 178 pg/mL led to sensitivities and 
specificities of 78% and 95%, respectively, in determining PPID. The same researchers showed 
that evaluating the ACTH concentration at 30 minutes improved their sensitivity and specificity 
to 90% and 96%, using a cut off of 209 pg/mL in the autumn and a sensitivity and specificity of 
87% and 86%, respectively in non-autumn months. In this study, there appeared to be an ability 
to differentiate between the normal, subclinical (not overtly PPID horse), and clearly 
hypertrichotic PPID horses. Chapman et al. (2017) reported on using 3  (0.5 mg, 1 mg and 2 mg) 
and Stallenberger et al. (2017) on 2 (0.5 mg and 1 mg) different amounts of TRH to perform the 
stimulation test with no significantly different mean plasma ACTH concentrations noted between 
groups after stimulation in either study. 
 
A combined test (using dexamethasone suppression and TRH stimulation) has been advocated 
historically (Frank et al. 2006) as increasing the specificity (76%) and sensitivity (88%) of 
diagnosis above that of either single test alone. The positive and negative predictive values were 
71% and 90%, respectively. 
 
Given the effect of exogenous prolactin on hair shedding in the horse, Schott et al. (2017) 
assessed the use of blood prolactin concentrations for use as a screening test for PPID in the 
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horse. These researchers found that while prolactin levels were higher in PPID horses, the 
variability was such that the sensitivity and specificity was only 77% and 54%, respectively, with 
a cut-off of greater than 3.5 ng/mL. It was, therefore, deemed not to be of use as a screening test. 
 
Horses with PPID have been reported to lose the cortisol circadian rhythm (Dybdal et al. 1994). 
As such, less than a 30% difference between morning and evening serum cortisol concentrations 
was considered as a possible diagnostic test (Douglas 1999), however, it ultimately proved 
unsuitable for several reasons. Firstly, there is a normal loss of circadian rhythm inherent with 
aging and also with generalized disease. Secondly, even in the absence of disease, the amplitude 
of the variation over the course of a day is low. Added to this, there are a myriad other factors 
such as stress, feeding, and exercise that can alter the basal cortisol levels to the point that 
determining a useful cut-off value between PPID and normal horses has proven difficult 
(McFarlane 2011; Cordero et al. 2012). Interestingly, a recent study found that tear concentration 
of cortisol in PPID horses was found to be higher than aged control horses, despite there being no 
significant difference in serum cortisol concentrations. Additionally, the ratio between tear and 
serum cortisol concentrations was higher in PPID than in aged controls (Hart et al. 2016). The 
focus of the paper was on the delayed corneal wound healing in PPID horses. It is possible that 
this easily obtained sample might be useful as a diagnostic test in the future. 
 
Another possible avenue for PPID diagnosis is proteomics. McFarlane et al. (2017) are 
developing a diagnostic test based on matrix-assisted laser desorption/ionization (MALDI)-Time 
of Flight (TOF) Mass Spectrometry. This methodology differs from the previously mentioned 
tests in that it seeks out plasma peptide signatures and is based upon the premise that in PPID 
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there are a significant number of altered peptides and POMC derivatives in the circulation that 
are not present in the normal horse. Thus far, it is in the design and testing phase but may 
represent the next quantum leap in the early diagnosis of PPID in the horse.  
 
1.6.2 IMAGING 
 
The recent advent of advanced diagnostic imaging modalities has not been used to its full 
advantage in PPID. Magnetic resonance imaging (MRI) is the chosen modality for soft tissue 
imaging. There are 2 different types of MRI unit available for use in the horse: a high-field (3 
Tesla) machine requiring general anesthesia, the use of which has been reported in the 
assessment of the pituitary gland of PPID horses (Schott et al. 2015); and a smaller, low field (1 
Tesla) unit designed for standing animals. Standing cranial MRI using the smaller, low field units 
would limit cost and improve availability of technology. However, bore size – the area into 
which the region of interest must fit – precludes brain imaging in mature horses, which 
specifically excludes use in PPID patients. 
 
Computed tomography (CT) is a technique that is best used for bone imaging, although good soft 
tissue delineation is also possible. CT is routinely used for imaging the distal limbs and heads of 
equine patients under general anesthesia and, more recently, standing CT examination of the 
equine head has gained popularity in some academic institutions and private practices. The 
ability to use the latter modality in a standing horse reduces both cost and risk for the equine 
patient. Imaging of soft tissues can be improved by contrast enhancement as illustrated succinctly 
in a paper reporting the use of high volume (240 mL) intravenous contrast enhancement to 
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improve the ability of researchers to delineate areas of damaged cerebrum in a study of 
neurological horses (Lacombe 2010). CT has been used with and without contrast enhancement 
to assess the ability to accurately measure the size of normal equine pituitary glands in-vivo 
(McKlveen et al. 2003) and, most recently, contrast enhanced computed tomography was used to 
study the effect of long term medical treatment of horses with PPID using pergolide mesylate 
(Pease et al. 2011). Problems associated with contrast enhancement of the brain tissues using the 
published methodology were that the high volume of contrast material represented a significant 
cost. Additionally, the use of intravenous contrast material resulted in volume dilution of the 
medium throughout the body tissues with proportionately less being distributed in the soft tissues 
of the brain. Theoretically, by targeting a specific body-part, i.e., delivering the contrast material 
solely to this region, the volume depletion effect would be reduced, and result in superior image 
quality and reduced cost. Using specifically-timed contrast-enhanced diagnostic imaging would 
also allow the arterial supply to the pars intermedia of the pituitary gland to be elucidated. 
Comparison of the information obtained from normal horses with that obtained from horses with 
PPID may allow interventional cerebrovascular surgery to be performed in PPID patients (see 
Chapter 6). 
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1.6.3 NECROPSY 
 
Necropsy and histological examination of the pituitary gland long-represented the definitive 
diagnostic test for PPID. However, the hypophysis undergoes age-related morphological change 
in both the pars intermedia and the pars distalis (Leitenbacher and Herbach 2016), complicating 
the definitive diagnosis of PPID. The hypophysis is typically 2 to 5 times larger in horses with 
PPID than in unaffected horses, which is due to a combination of hypertrophy and hyperplasia of 
the cells of the pars intermedia. These melanotrophs are present in nodules or follicular structures 
separated by fine connective tissue (Boujon et al. 1993; van der Kolk et al. 2004; Glover et al. 
2007; Miller et al. 2008). Given that there is considerable overlap in the size, weight and density 
of PPID and normal hypophyses, a histological grading system was developed (van der Kolk et 
al. 2004). In this system, histologic lesions of the pars intermedia, pars distalis, or both, were 
determined to be 0 if there were no lesions; 1, if there were single or multiple cysts; 2, if there 
was focal or multifocal hyperplasia; 3, if there was a single or multiple microadenomas 
(arbitrarily classified as being less than 5 mm in size); and 4, if there was a macroadenoma 
(greater than 5 mm in size). McFarlane et al. (2005) subsequently reported that histological grade 
only correlated with antemortem diagnostic test results 79% of the time.  Miller et al. (2008) 
were the first to develop a 1 to 5 graded scoring system and reported that only adenomas graded 
as 3 or higher were associated with elevations in plasma ACTH levels after stimulation with a 
D2R antagonist (domperidone), and it may simply be that the diagnostic tests are not sensitive 
enough to detect the hormonal changes and that the systemic response to the elevations in 
POMC-derived peptides may have yet to reach the lower-limit of response. More recently, a 
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modification of this system was reported by Leitenbacher and Herbach (2016) where grade 1 
represented a normal pituitary gland. Increasing grades represented gradual increases in 
abnormality such that grade 2 was assigned to focal or multifocal enlargement of the pars 
intermedia, grade 3 was diffuse enlargement of the pars intermedia, grade 4 represented diffuse 
enlargement of the pars intermedia with microadenomas (less than 5 mm in diameter) and grade 
5 was diffuse enlargement with macroadenomas (greater than 5 mm). Despite the age-related 
changes to the equine hypophysis, the authors reported that a definitive diagnosis of PPID could 
be made using a combination of pituitary weight and quantitative stereological change, 
specifically the volume of the pituitary gland and the volume of the pars intermedia. Pars 
intermedia adenomata were also classified as non-functional (or age-associated) or PPID-
associated adenomas, depending on the evidence of clinical signs of PPID. The latter 
classification is controversial as there is no evidence to suggest that microadenomata are non-
functional. 
 
1.7 TREATMENT  
1.7.1  MEDICAL 
 
PPID results in a disease syndrome of the older horse and as such a holistic approach to 
management must be taken. The provision of sufficient shelter, water, appropriate diet and 
general husbandry, such as the routine maintenance of both oral health and podiatry, are 
important. 
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The drug of choice is pergolide mesylate, an ergot-derived D2R agonist which down regulates 
POMC-derived peptide production via a G-protein coupled mechanism. This drug needs to be 
given for the life term of the horse. Efficacy of this drug has been well documented (Munoz et al. 
1996; Schott et al. 2001; Donaldson et al. 2002; Perkins et al. 2002; Sgobini et al. 2004). It was 
initially used for the treatment of human Parkinson’s disease, but removed from the market due 
to its association with valvular endocarditis. An exemption was made for compounded products 
to be used for equine PPID, however, the efficacies varied due to instabilities in aqueous carriers 
and the compounded product had to be stored in the refrigerator (Davis et al. 2009). Recently, a 
new equine pergolide product has been approved by the Federal Drug Administration in the USA 
and Health Canada in Canada, and is also being used in Europe (Prascend, Boehringer 
Ingleheim). Treatment is usually initiated as 1 mg per horse and the dose is titrated up, in 0.5 mg 
or 1 mg increments, until clinical and clinicopathological features of the disease are normalized. 
Therapeutic monitoring can be performed, however, these hormone-response tests may take 
several months to normalize (McFarlane et al. 2017). Why these responses take such a long time 
to normalize is difficult to understand when pharmacokinetics and pharmacodynamics of oral 
pergolide mesylate showed that the pergolide concentration reached a steady state within 3 days 
of the initiating treatment. There was a concurrent significant reduction in the plasma ACTH 
concentration and the authors of this study (Rendle et al. 2017) suggested that earlier follow-up 
testing may be possible. There is also a suggestion (McFarlane 2011) that individual 
requirements may increase over time, as occurred in human Parkinson’s patients and there may 
also be a season effect, with additional pergolide being needed to control ACTH concentrations 
in PPID horses in the summer and fall (McFarlane et al. 2017).  
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Two other drugs have been used in the management of PPID. Cyproheptadine, a serotonin 
antagonist with an antihistamine and an antimuscarinic effects has been used, however, in studies 
comparing the efficacy of either cyproheptadine or pergolide in normalizing the clinical signs 
associated with PPID, there was either no difference between the drugs (Perkins et al. 2002) or a 
superiority of pergolide (Donaldson et al. 2002). Cyproheptadine has been used in combination 
with pergolide in refractory cases of PPID (Donaldson et al. 2002; Perkins et al. 2002). Trilostane 
has been reported to improve the clinical signs (primarily laminitis, PU / PD and lethargy) 
associated with PPID, but not the dexamethasone suppression test results (McGowan et al. 2003). 
It is a competitive inhibitor of 3b-hydroxysteroid dehydrogenase, the enzyme responsible for 
production of cortisol from cholesterol. As such, this drug may improve the clinical signs of 
PPID in the small percentage of horses with adrenal gland hyperplasia, but has no effect on 
pituitary derived hormones. 
 
1.7.2 SURGICAL 
 
Surgical intervention in the treatment of human brain tumors is common. These procedures can 
be performed via a craniotomy; “key-hole” approaches using stereotaxic guidance; 
cerebrovascular neurosurgery (blocking specific arteries to tumors to cause hypoxic necrosis); 
neuroendoscopically; or specifically in some cases of tumors of the pituitary gland, via a trans-
nasal approach (Krisht 2002; Cappabianca 2004). Pituitary tumors in cats and dogs have also 
been removed (Meij 1997) using a trans-oral approach with relapse-free rates in dogs being 
reported as 92% (Meij et al. 1998) and 91% at 1 year and 80% at 2 years (Meij et al. 2002). 
Initial reports of surgery in canine pituitary-dependent Cushing’s disease were exciting in that 
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they reported that residual cells left within the sella turcica hypertrophied resulting in a lack of 
need for post-surgical hormone therapy (Meij et al. 1997). Unfortunately, later publications 
indicated that this was likely a result of incomplete removal of the initial adenoma (Meij et al. 
2002). 
 
Brain surgery is rarely performed in the horse. There are single case reports of the drainage of a 
brain abscess after localization using CT (Allen et al. 1987; Cornelisse et al. 2001; Janicek et al. 
2006) and a CT-guided biopsy of an intra-cerebral mass which was subsequently diagnosed as a 
cholesterinic granuloma (Vanschandevijl et al. 2008). Kramer et al. (2007) reported on 3 
approaches to the equine cranium (rostrotentorial, suboccipital and the transfrontal) in cadaver 
heads, which gave limited access to the rostral, dorsal and caudal aspects of the cerebral cortex 
and cerebellum. No described approach gave access to the hypophysis. There is a single case 
report of an open craniotomy and severing of the hypothalamic-pituitary axis using a laser 
(Locatelli 1984), which unfortunately does not describe the technique or outcome sufficiently 
well to allow repetition. It is important to note that any surgical intervention in the PPID horse 
must represent an improvement on current medical treatment modalities. Namely, there should 
be no need for daily medication beyond the immediate post-surgical phase. Essentially, this 
means that abnormal melanotrophs from the pars intermedia need to be excised en-bloc, or 
otherwise disabled, without damage to the other important regions of the gland. This may seem a 
difficult task, given that the pars intermedia is interposed between the pars distalis and the pars 
nervosa; however, in end-stage (Grade 5) pituitary glands the pars distalis is often reduced to a 
thin strip of tissue on the outside of the grossly enlarged gland, meaning that the potential for 
damage may be lessened. 
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Potential surgical approaches to the hypophysis include myeloscopy via a foramen magnum 
access point; a trans-sphenopalatine sinus approach; a ventral craniotomy (using a Viborg’s 
triangle or trans-laryngeal approach) via a slot-ostotomy of the basisphenoid bone; or possibly, 
cerebrovascularly. The orientation of the equine brain relative to the long axis of the head is 
approximately parallel, as with most quadrupeds. However, it is the anatomical arrangement of 
the paranasal sinuses in this species that imparts a critical difference to any potential surgical 
approach to the sella turcica. In addition to this, as the pars intermedia enlarges there may also be 
an as yet unreported alteration in the orientation (size and shape) of the gland, which would have 
major implications on any surgical intervention or invasive treatment. 
 
As noted above, Vitums (1975) specifically did not examine the arterial anatomy of the pars 
intermedia of the equine pituitary gland. If the arterial vascularization of the pars intermedia can 
be substantiated it may be that, with contrast enhancement, the neovascularization associated 
with adenomatous expansion in PPID can be visualized and subsequently occluded via 
fluoroscopy, CT or MRI-guided coils. This approach may be the least invasive and most elegant 
treatment. Another option may be to use the venous access as described by Vitums (1978) and 
exploited by Irvine et al. (1984). If catheterization of the ventral cavernous sinus for blood 
sample collection is possible, then access to the pituitary gland for treatment purposes, as 
described by Sakes et al. (2015), is a realistic and exciting minimally invasive approach. 
 
Despite the fact that PPID was first reported 85 years ago, only recently have some 
pathophysiological mechanisms been described. Similarly, there is only 1 common treatment, 
which was first described 30 years ago. A further understanding of the pathophysiology of 
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disease, an early, definitive diagnostic test and a less onerous treatment for this chronic condition 
is needed. 
 
1.8 GENERAL OBJECTIVES AND SPECIFIC AIMS 
 
The long term goal of this research is to explore the feasibility of developing a targeted tissue-
specific approach for the treatment of equine PPID. This thesis constitutes a first approach to this 
goal. The specific aims of this thesis are: 
 
1. To confirm the need for this advanced therapy by determining the prevalence of PPID 
in horses globally (Chapter 2). 
 
2. To continue the investigation of the underlying cellular mechanism of PPID by 
sequencing the POMC, PC1 and PC2 genes, identifying a suitable internal control 
gene for use in the equine pituitary gland, examining gene expression of pro-hormone 
convertases, and quantifying the differences in POMC, ACTH, αMSH and CLIP 
hormone concentrations in affected and unaffected horses (Chapter 3). 
 
3. To investigate the methodology for site-specific application of future therapy for 
equine PPID (Chapters 4, 5, and 6). 
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FOOTNOTES 
a https://www.talkaboutlaminitis.co.uk/ 
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CHAPTER 2 
 
TRANSITION PAGE 
 
 
Equine pituitary pars intermedia dysfunction: An international survey of veterinarians’ 
approach to diagnosis, management and estimated prevalence 
This chapter presents an international survey completed by equine practitioners from 20 
countries. This serves as a basis upon which to investigate PPID further. Important 
geographical differences were found in the methodology of diagnosis. Cost and management 
responsibilities associated with treatment were described as client concerns by veterinarians 
completing the survey. 
This survey was important to bring an international perspective to the diagnosis and 
management of this chronic equine condition. Additionally, it verifies the need for either a long-
acting therapy, or a 1-time treatment, to bring about a cure and improve the welfare of aged 
horses. 
Copyright statement:  Chapter 2 has been submitted for publication. The copyright of this 
Chapter will belong to the journal in which it is published. 
Full citation: Carmalt JL, Waldner CL and Allen AL. Equine pituitary pars intermedia 
dysfunction: An international survey of veterinarians’ approach to diagnosis, management and 
reported prevalence. Can J Vet Res, 2017. Accepted. 
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2.1 ABSTRACT 
 
Objectives: To determine if the diagnosis and treatment of pituitary pars intermedia dysfunction 
(PPID) varies by geographic region and to estimate the prevalence of PPID in horses as observed 
by veterinarians across locations. 
Materials and Methods: An online questionnaire was developed for equine veterinarians. 
Veterinary associations, especially equine specialty sub-groups, were contacted and a survey link 
was sent to members of each organization. Generalized linear models were used to examine 
whether the method of diagnosis and treatment of this condition, as well as reported prevalence, 
differed by geographic region. 
Results: 426 veterinarians from separate clinics completed surveys. Diagnosis was usually based 
on clinical signs and an endogenous adrenocorticotrophic hormone test. Treatment was typically 
medical (63% of respondents) of which 75% used pergolide mesylate. The estimated prevalence 
was 1% which did not differ by geographical location. Half of veterinarians had 5 or more 
animals with PPID under their care. 
Conclusions: Geographic differences exist in the diagnostic approach, but not the estimated 
prevalence of clinical disease. Cost and management responsibilities associated with treatment 
were described as client concerns by veterinarians. 
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2.2 INTRODUCTION 
Pituitary pars intermedia dysfunction (PPID), also known as equine Cushing’s disease, is a 
commonly diagnosed endocrinopathy of older horses (Toribio 2005). Clinical signs are typically 
noted in horses older than 18 years and are rare in horses under 10 (Schott 2002; Orth et al. 
1982). 
 
The estimated prevalence of PPID is varied and depends on the age of horses in the referent 
population, as well as the method (i.e., owner reports versus diagnostic tests) used to effect the 
diagnosis (Table 1.1). Johnson et al. (2011) state that “conservative estimates of the prevalence 
of the condition range from 0.07% to 0.5% of the equine population”, and Rohrbach et al. (2012) 
report an increase in the rate of diagnosis from 0.025% to 0.37% between 1993 and 2002. 
However, as the horse population ages, the prevalence increases: 3.3% in horses over 15 years in 
Great Britain (Ireland et al. 2011), 10% in horses over 20 years in North America (Brosnahan and 
Paradis 2003) and 14% to 21% in similarly aged horses in Australia (McGowan et al. 2013). 
 
The proposed pathophysiology of PPID is a loss of dopaminergic inhibition of melanotrophs in 
the pars intermedia of the pituitary gland leading to hyperplasia and hypertrophy. The inciting 
cause is unknown, but oxidative damage to the hypothalamic dopaminergic neuronal soma is 
thought to play an important role (McFarlane et al. 2005; Glover et al. 2009). The prevalence of 
Parkinson’s disease, a human dopamine-associated neurodegenerative disorder, varies among 
geographic regions with higher prevalence in northern and agricultural North American states 
compared to southern and industrialized areas (Priyadarshi et al. 2001; Wright 2010). It is 
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unknown if such a geographical effect exists for equine PPID, whether it be regional or global.  
 
Domesticated horses are living longer as they are increasingly being managed as companion 
animals (Welsh et al. 2016). As such, the frequency with which veterinarians are asked to 
diagnose and manage PPID would be expected to rise. The objectives of the study were to 
determine whether veterinarians were diagnosing and treating this important chronic disease in 
similar fashion across different geographical regions while accounting for any differences 
veterinarians reported in estimated prevalence of PPID. 
 
2.3 MATERIALS AND METHODS 
 
A survey was developed (Appendix A) and pilot tested with veterinarians experienced in the 
design and implementation of survey tools. The final product was translated into French and 
Spanish and all 3 versions were managed online for 18 months (January 2012 to June 2013)a. 
Institutional ethics approval was not required because no personal data was requested from 
respondents. 
 
The survey was brought to the attention of equine practitioners by contacting international 
colleagues, national and state (USA and Australia) or provincial (Canadian) veterinary 
organizations, as well as international equine veterinary groups, including equine sub-specialties 
of the national associations of individual countries (Appendix B). These groups then notified 
their respective members through e-mail, digital bulletins and newsletters. Six months after 
original contact, all groups were asked to send a second notification to their membership. Paper 
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surveys were also produced and distributed by the authors at the annual meeting of the American 
Association of Equine Practitioners (2012; Anaheim, California) and completed results were 
added to the database. All results were compiled using a Windows-based spreadsheet programb 
and then moved to a commercial statistical package for analysisc. 
 
Linear regression was first used to look at differences in practice-level prevalence reported by 
veterinarians as a percentage of their caseload (denominator not available) by both practice type 
and among geographic regions, as this was considered a factor that might subsequently impact 
approaches to diagnosis and treatment. Poisson regression with a log link function was used to 
examine the effect of potential risk factors on the number of PPID diagnostic tests used by 
veterinarians. Logistic regression was used to evaluate potential risk factors for the decision to 
use a diagnostic test (1) in addition to clinical signs alone (0); similarly, to determine the 
potential risk factors behind the decision to use the most common endocrinologic test (1) as 
opposed to other endocrinologic test options (0); whether the primary disease – what is assumed 
to be a functional pituitary tumor – was treated (1) or not (0); and if treated with commercial (1) 
versus compounded (0) pergolide (if available). All potential risk factors were initially screened 
using unconditional analysis and variables where p-values < 0.2 were considered in building the 
final multivariable model (Dohoo, Martin and Stryhn 2012). All final models were built using 
manual backwards elimination. Variables considered in model building that were not significant, 
and that were not mediators, were assessed as potential confounders of associations of interest 
that were identified during the analytical process. Where 2 or more variables were significant, 
biologically plausible 2-way interactions were assessed with interactions retained in the final 
model and reported if the type-3 likelihood ratio test was significant (p < 0.05). Differences, 
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where p < 0.05 were considered significant, and appropriate measures of effect and 95% 
Confidence interval (CI) were reported for each analysis. 
 
The number of horses under the care of veterinary practitioners was highly skewed and 
associations between this variable and the outcomes of interest were not linear. As such, the 
number of horses under the care of each veterinarian was categorized using cut-off limits based 
on the 25%, 50% and 75% data quartiles as follows: 1 to 2 horses, 3 to 4 horses, 5 to 20 horses, 
and 21 to 250 horses. 
 
Not all questions were answered by all respondents. For other questions, such as country of 
veterinary practice and practice type, there was only 1 respondent from each of South Africa, 
Chile and Jordan. Countries were consolidated into geographical regions (Table 2.1) for analysis 
with elimination of single respondent regions. For these reasons not all analyses had the same 
number of included observations. Specific inclusion criteria and respondent numbers are reported 
in the appropriate sections of the results. 
 
2.4 RESULTS 
 
There were 426 respondents each representing a single clinic; 404 responded in English, 12 
responded in French and 10 responded in Spanish. Two hundred and eighty-seven respondents 
(67.4%) from 20 countries completed the question on practice location of whom the majority,  
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Table 2.1 Number of veterinary responses tabulated by country and grouped by 
                 geographic region. 
  
Geographic Region 
Country 
Total number 
of respondents 
from each 
country 
Percent 
of total 
number 
Percent of total 
number of reported 
practice country 
     
North America  181 42.5 63 
 Canada 83 19.5 28.9 
 USA 98 23 34.1 
South America  1 0.2 0.3 
 Chile 1 0.2 0.3 
Europe  73 17.2 25.3 
 Belgium 6 1.4 2.1 
 Denmark 5 1.2 1.7 
 France 3 0.7 1 
 Germany 30 7 10.5 
 Italy 2 0.5 0.7 
 Netherlands 2 0.5 0.7 
 Northern Ireland 1 0.2 0.3 
 Norway 2 0.5 0.7 
 Portugal 2 0.5 0.7 
 Spain 6 1.4 2.1 
 Sweden 5 1.2 1.7 
 United Kingdom 9 2.1 3.1 
Middle East  1 0.2 0.3 
 Jordan 1 0.2 0.3 
Australasia  31 7 10.4 
 Australia 23 5.4 8 
 Japan 4 0.9 1.4 
 New Zealand 3 0.7 1 
Africa  1 0.2 0.3 
 South Africa 1 0.2 0.3 
     
 Reported 287 67.4 100 
 Unreported 139 32.6  
 Total 426 100  
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34.1% (98/287), were from the U.S.A, 28.9% (83/287) were from Canada, and 10.5% (30/287) 
were from Germany. Countries were grouped into geographical regions (Table 2.1). Practice 
category was widely varied (Table 2.2) and encompassed equine specialists as well as combined 
small animal and equine practitioners, and general mixed animal veterinarians. Most respondents 
worked in private practice (Table 2.3).   
 
Of the 426 veterinarians completing the survey, 360 (84.5%) reported at least 1 horse with PPID 
in their practice. The median number of PPID animals under the care of the study respondents 
was 5 (25% and 75% IQ range 3 to 20). These animals represented a median of 1.0% (25% and 
75% IQ range 0.1 to 5.0) of their equine practice case-load. The median age of affected horses 
was 20 years (25% and 75% IQ range 18 to 22; mean 19.7 +/- SD 4.3, range 9 to 35 years).  
 
Overall, 67.2% (242/360) of veterinarians reported managing PPID horses by treating, what was 
assumed to be a functional pituitary tumor, with drugs. Of the remaining 32.8% (118/360), only 
34 of the respondents elaborated as to why they offered no treatment. Seventy-nine percent 
(27/34) of these veterinarians indicated that client limitations prevented the clients from treating, 
while treatment was not warranted in 17% (6/34), or the lack of drug availability prevented them 
from treating (3%, 1/34). Reasons for client limitations were reported as financial (66.7%; n = 
25) or perceived responsibility of long-term management (33.3%; n = 14). Some respondents 
reported that both financial and responsibility of long-term management were limiting reasons. 
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Table 2.2 Distribution of respondents by practice categories 
 
Practice Category Number Overall 
Percentage 
Percentage of 
Reported Practice 
Categories 
     
 
Equine only (Specialty) 132 31.0 44.0 
Large Animal (Equine Predominant) 40 9.4 13.3 
Large Animal (General) 16 3.8 5.3 
Combined SA and Equine 47 11.0 15.7 
General Mixed 65 15.3 21.7 
    
Reported 300 70.4 100.0 
Unreported 126 29.6  
 Total 426 100.0  
 
 
 
 
Table 2.3 Distribution of respondents by practice type 
 
Practice Type Number of 
Respondents 
Overall 
Percentage 
Percentage of Reported 
Practice Types 
    
Private Practice 274 64.3 92.6 
Academia 17 4.0 5.7 
Government 3 0.7 1.0 
Industry 2 0.5 0.7 
    
Reported 296 69.5 100.0 
Unreported 130 30.5  
Total 426 100.0  
 
 64  
Of those veterinarians with at least 1 PPID horse under their care, 67.2% (242/360) 
recommended medical treatment, while a small number reported using other options such as 
dietary management (8), herbal therapy (4), exercise (3), acupuncture (3), immunomodulation 
(2), and parasite management (1). Some chose not to treat (46/360) and some respondents 
(66/360) did not describe their treatment recommendations.  
 
Additionally, other veterinarians reported using different management strategies in some cases 
(hence the numerator is greater than the denominator), but did not elaborate as to what influenced 
their choices. Overall, pergolide mesylate was the most commonly reported form of medical 
treatment (n = 271) as either the compounded (136) or commercially available (135) form. 
Commercial cyproheptadine (6), trilostane (5), and bromocriptine (2) were also used. Some 
veterinarians reported using more than 1 product on the same horse and, therefore, the sum of 
treatments exceeds the number of respondents. 
 
Most respondents (71.0%, 303/426) indicated that they thought PPID was an important equine 
disease. Fifty-four percent of veterinarians (228/426) indicated that a new approach to the 
management or cure of the disease was necessary.  
 
The dataset was then limited to veterinarians working in private and academic practice in North 
America and Europe (n = 254). None of the variables examined, including geographical region (p 
= 0.61) or practice type (p = 0.61), were associated with the estimated prevalence of disease. 
Similarly, the number of animals reported as being under the care of each respondent did not vary 
by geographic region (p = 0.96). The number of animals under care did vary by practice category 
 65  
(p = 0.004), where those respondents in equine only (specialty) practice had more PPID horses 
under their care than veterinarians in mixed small animal / equine practices and general practice 
(p = 0.002 and 0.001, respectively). There was no difference between those in large animal / 
equine (p = 0.15) or large animal practice (p = 0.64), and there were no significant differences 
among other categories. 
 
Equine veterinarians from North America and Europe that have PPID horses under their care (n = 
208) typically used a single diagnostic test to determine whether a horse had PPID (median 1, 
25% and 75% IQ range 1 to 2; mean 1.4 +/- 0.63, range 1 to 4), and this number varied by 
geographical location (p = 0.046), but not based on the characteristics of the practice surveyed (p 
= 0.13). Some respondents reported using clinical signs as their only diagnostic test (56/208, 
27%). In the final model of factors affecting whether a practitioner used only clinical signs, or 
clinical signs and an additional test to diagnose PPID, the only significantly associated variable 
was geographical location (p = 0.01). The odds of European veterinarians using clinical signs 
alone to diagnose PPID was higher than for North American veterinarians (OR 5.35, 95% CI = 
2.1 to 14.2). 
 
If veterinarians chose to use a diagnostic test in addition to clinical signs, the most common 
adjunct test was a determination of endogenous adrenocorticotrophic hormone (ACTH) 
concentrations. The final model identifying the factors associated with whether a practitioner 
chose to diagnose PPID using clinical signs and endogenous ACTH compared to clinical signs 
and any other additional test included only the number of horses under the care of the 
veterinarian. Veterinarians with less than 5 horses with PPID under their care were more likely to 
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use endogenous ACTH, as compared to another test, in addition to clinical signs than those 
veterinarians with greater than 5 horses (OR = 5.0, 95% CI = 1.3 to 18.9, p = 0.009).  
 
None of the factors examined, including geographical region (p = 0.31), were associated with 
whether a respondent decided to treat PPID medically as compared to leaving the horses 
untreated. North American and European respondents’ choice of drug to treat PPID included 
commercial pergolide mesylate (n = 100), compounded pergolide mesylate (n = 98), 
cyproheptadine (n = 5), commercial trilostane (n = 3) and bromocriptine (n = 2). Some 
respondents used more than 1 drug. 
 
2.5 DISCUSSION 
 
The objectives of this survey were to investigate whether veterinarians in different geographical 
regions used similar strategies in the diagnosis and treatment of PPID while accounting for any 
differences in the estimated prevalence of PPID as reported by these veterinarians. We attempted 
to encourage a wide variety of respondents by actively inviting a spectrum of veterinarians, from 
those who were in general mixed practice with at least some equine cases to those in specialty 
practices where 100% of the caseload was equine. 
Eighty-four percent of respondents had at least 1 horse with PPID under their care, with half of 
veterinarians reporting at least 5 horses with PPID. This data shows that most veterinarians 
servicing the horse industry have to deal with this chronic, debilitating problem. Our results 
suggest that European veterinarians were more likely to use clinical signs alone for diagnosis 
than colleagues in North America. The reason behind this difference is intriguing and deserving 
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of further investigation. By waiting until the pathognomonic clinical appearance of advanced 
PPID is evident, some European veterinarians might be waiting longer than necessary before 
instituting treatment to ameliorate the biochemical abnormality associated with this condition. 
However, given the ready availability of a commercial medical treatment with proven efficacy 
and few negative sequelae beyond cost for treating an incorrectly diagnosed patient, additional 
diagnostics could potentially be perceived as not being cost efficient. Unfortunately, the response 
rate for our study was not sufficient to detect differences, if any, among European countries. 
 
Taking all responses into consideration, 30% of respondents in our survey used clinical signs, 
i.e., hypertrichosis, as the sole diagnostic criterion in the diagnosis of PPID. This may appear 
inadequate, however, hypertrichosis has been reported as having a positive predictive value 
(PPV) of 90% (Frank et al. 2006). This is a high value, but the calculation of PPV is intimately 
associated with the prevalence of disease. Since the authors of that paper selected their case 
population as being suspicious of PPID, and then confirmed the diagnosis using post-mortem 
examination, the prevalence of disease was high (62%). The specificity and sensitivity of the test 
was reported as 95% and 71%, respectively. In our study population, where veterinarians 
reported an estimated prevalence of PPID of 1% in their practice populations, the use of 
hypertrichosis alone would generate a PPV of only 14%. The negative predictive value (NPV) of 
a lack of hypertrichosis in this population, however, is greater than 99%. The evaluation of 
hypertrichosis in older horses results in an increased PPV because they have a higher pretest 
probability of disease (McGowan 2013). The probability of a false positive diagnosis in an aged 
horse with hypertrichosis should be much lower due, in part, to the limited list of possible 
alternative diagnoses. Rohrbach et al. (2012) reported that 34% of 44 horses and ponies with 
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PPID were diagnosed solely on the basis of hypertrichosis, with another 23% based on a 
combination of hypertrichosis and the result of a dexamethasone suppression test. The authors 
stated that when present, hypertrichosis was considered as accurate as laboratory-identified cases. 
However, the sensitivity is not 100% and the resulting NPV in high risk horses will not be 
greater than 99%. Three percent of horses with a pituitary pars intermedia adenoma at necropsy 
did not show any clinical signs associated with PPID including hypertrichosis (Okada et al. 1997; 
van der Kolk et al. 2004).  
 
Dybdal et al. (1994) reported that all PPID horses had a plasma cortisol concentration of greater 
than 27.6 nmol/L (1 μg/dL) at 20 hours post dexamethasone administration, whereas all control 
horses had serum cortisol concentrations less than 27.6 nmol/L. Subsequently, Frank et al. (2006) 
reported that the dexamethasone suppression test had a sensitivity of 65% and a specificity of 
76% in a population of horses, whose age ranged from 2 years to 33 years, in which the diagnosis 
was ultimately determined by necropsy assessment of the pituitary gland. Most respondents to the 
survey question used resting plasma ACTH concentration (van der Kolk et al. 1995; Couëtil et al. 
1996) as their adjunct diagnostic test of choice. This has a reported sensitivity between 80% and 
84% with a specificity of between 78% and 83%, using different cut-off values, of 29.7 pg/mL 
(McGowan et al. (2013) and 35 pg/mL (Perkins et al. (2002), using hypertrichosis and 3 or more 
clinical signs of PPID in seasons other than autumn. It is important to note that early papers 
citing diagnostic cut-off values may be misleading as they were published before the seasonal 
variation in ACTH concentration was recognized (Donaldson et al. 2005). The differences in the 
specificity and sensitivity of the dexamethasone suppression and the endogenous ACTH tests 
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may explain why the use of the dexamethasone suppression test, as well as the reported risks of 
inducing laminitis, has fallen out of favor. 
 
For the aged horse with hypertrichosis, use of an additional test with the above mentioned 
specificities and sensitivities (the presence of hypertrichosis and endogenous ACTH testing) only 
decreases the probability of detecting a false positive (1-Specificity) PPID horse from 5% to 
about 1% assuming serial interpretation of the test results from clinical diagnosis followed by the 
endogenous ACTH test.d Depending on the estimated prevalence of the disease in that age of 
horse, the PPV is not substantially improved by using the combined approach, questioning the 
benefit of additional testing to rule-in disease in animals with clinical signs. It was interesting to 
find that veterinarians with fewer than 5 horses under their care were more likely to use 
laboratory corroborative testing than those with greater than 5 horses. The reasoning behind this 
choice is not known, however, we speculate that perhaps those with greater numbers of PPID 
animals under their care are more confident in using only clinical signs, because of their greater 
professional experience. 
 
One limitation of the data obtained from this survey, as well as that in the existing peer-reviewed 
literature, is that horses that are both confirmed with, and suspected of having, PPID are 
discussed together. Historically, horses that did not have hypertrichosis, despite advancing age, 
were infrequently tested and there is currently no consensus on a definitive diagnostic test for 
documenting PPID, especially in earlier stages of disease. As such, the true prevalence of disease 
may be much higher than reported (Donaldson, Jorgensen and Beech 2004; van der Kolk 2004; 
Rohrbach et al. 2012). The extent to which old horses and ponies, i.e., greater than 15 years, are 
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being tested has been subjectively increasing in recent years (especially in the UK and Australia, 
whose numbers are not well represented in the current survey), and there has been an emphasis 
on trying to detect and treat PPID before it becomes a welfare concern. A recent experimental 
study by McGowan et al. (2013) reported a PPID prevalence of 21.2% in horses over 15 years, 
based on endogenous ACTH concentration, despite the prevalence of hypertrichosis being only 
14.2%. In this scenario (aged horse with no apparent hypertrichosis), the addition of endogenous 
ACTH testing interpreted in parallel with clinical signs (again, with the above mentioned 
specificities and sensitivities) will improve the sensitivity of a diagnosis of PPID from 71% with 
clinical signs alone, to 95% for animals with a concurrent positive ACTH test.d This shows that 
the use of adjunct testing methodologies earlier in the disease process, or as a screening test in 
horses over 12 to 15 years of age, can allow earlier diagnosis and treatment of disease. This may 
improve the health of the horse and extend the usefulness of the animal to the client. As a 
profession, we can and should strive to diagnose this condition earlier and thus improve the 
quality of life for aging horses.  
 
Most respondents reported treating individuals suspected to be affected with PPID, and most of 
them used pergolide mesylate. Commercial and compounded product was equally represented 
overall. Unfortunately, the survey did not explore the extent to which commercial versus 
compounded form of pergolide was available to the respondents, as this may have significantly 
affected their choice of product, especially as the compounded pergolide has been shown to have 
substantial limitations, such as a lack of stability depending on the vehicle and storage conditions 
(Stanley and DiMaio Kynch 2010; Davis et al. 2009).  
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Of the small number of participants elaborating as to why they did not treat affected horses 
almost 80% reported that financial and management limitations reported by their clients 
precluded treatment. Some veterinarians cited both reasons. This may explain why, despite the 
availability of a drug with proven efficacy (Munoz et al. 1996; Perkins et al. 2002; Schott et al. 
2001; Donaldson et al. 2002; Sgorbini et al. 2004), over 50% of respondents stated that they 
would like to see a new treatment or cure developed for this debilitating condition. The current 
treatment is costly due to its ongoing nature, and is labor and management intensive. Treating a 
horse on a daily basis may not seem overly onerous, however, in extensively or pasture managed 
horses who are infrequently handled, the need for daily medication would preclude treatment. 
Similarly, there is a significant emotional stress put upon the caregivers of humans and animals 
with chronic ongoing disease processes (Thompson and Gustafson 1996; Kelly 2014). Earlier 
diagnosis and treatment of this condition could improve the welfare of the horse by reducing or 
preventing some of the clinical sequelae, but will do little to assuage the client concerns and 
emotional stress about the feasibility of daily medication. If an equally efficacious, yet much less 
labor intensive, treatment were to become available, it is possible that veterinarians and clients 
would explore this option. 
 
The data from this survey represent the information shared by the veterinarians who were 
interested enough in this issue to take the time to respond to the survey. Volunteer bias is a 
limitation of survey data, as it is for the recruitment of practices to provide access to client data. 
However, the results were not completely restricted to veterinarians with a strong interest in 
PPID as only 71% reported that it is an important disease.  
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A second challenge in this study resulted from working through third parties to distribute the 
survey link. Given that the number of member e-mail addresses for each distributing organization 
was not shared, the response rate was unable to be calculated. However, despite the increasing 
focus on privacy and confidentiality of distribution lists, the authors were fortunate that these 
organizations were willing to distribute the survey link. The number of total respondents was 
lower than was originally hoped, however, based on the resulting confidence intervals adequate 
power to explore regional differences and risk factors for important diagnostic and treatment 
practices was available. Most respondents were from North America, Europe and, to a lesser 
extent, the Asia-Pacific region.  However, as far as the authors are aware, this is the only study to 
provide a concurrent comparison among these regions. While it may be limited in its accuracy, 
our data reflect a cross-section of a larger number of clinics and geographical regions than has 
been previously reported, and suggest that there was not a substantial difference in the perceived 
prevalence of PPID among participating regions. The reasons for lower numbers of responses 
from regions other than North America and Europe are unknown. 
  
Finally, there are recall biases inherent in all survey responses, but there is no reason to believe 
that this would be different among different regions. The estimated prevalence was at greater risk 
from reporting errors than routine diagnostic and management practices. It was not considered 
practical to ask veterinarians to do a search of their client records, however, the focus of our 
discussion has been on diagnostic and treatment choices. 
 
Overall, the results of this international survey of equine veterinarians indicated there were 
differences in how veterinarians diagnose PPID, with European veterinarians more likely to 
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render a diagnosis without adjunct laboratory testing, regardless of the number of animals under 
their care, than North American colleagues. The estimated prevalence of the condition 
recognized by practitioners was approximately 1% of horses of all ages, with no apparent 
geographical variation. More specifically, there was no difference in estimated prevalence 
between the northern and southern hemispheres, and no difference between Canada and the USA. 
There is a need for additional treatment options for PPID as some veterinarians reported that their 
clients are concerned about cost and management restrictions surrounding the long-term 
treatment of PPID. 
 
Footnotes: 
a Vertical Response, San Francisco, California, USA 
b Microsoft Excel, Microsoft Canada Inc, Mississauga, ON, Canada 
c SPSS, IBM Canada Inc, Mississauga, ON, Canada 
d http://epitools.ausvet.com.au/content.php?page=2Tests 
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CHAPTER 3 
TRANSITION PAGE 
Profiles of pro-opiomelanocortin, encoded peptides, and their processing 
enzymes in equine pituitary pars intermedia dysfunction 
This chapter presents the results of sequencing the equine POMC, PC1 and PC2 genes. The most 
appropriate internal reference gene for the equine pituitary gland is described, as is the 
expression of POMC, PC1 and PC2 in PPID and normal horses. The concentration of POMC, 
ACTH, αMSH, CLIP, PC1 and PC2 in ventral cavernous sinus plasma of PPID and normal 
horses is reported. 
This work contributes to the understanding of the pathophysiology of PPID by confirming 
previously held assumptions that upregulation of PC1 and PC2 occurs in PPID. Partial 
sequences of POMC, PC1 and PC2 were submitted to GenBank, where previously there had only 
been computer predictions. Pituitary hormone concentrations confirmed upregulation in PPID, 
but used samples obtained from the ventral cavernous sinus resulting in values that were much 
higher than have previously been reported. 
Copyright statement:  Chapter 3 has been submitted for publication. The copyright of this 
Chapter will belong to the journal in which it is published. 
Full citation: Carmalt JL, Mortazavi S, McOnie R, Allen AL and Unniappan S. Profiles of pro-
opiomelanocortin, encoded peptides, and their processing enzymes in equine pituitary pars 
intermedia dysfunction. PLOS ONE, 2017. Submitted.  
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3.1 ABSTRACT 
 
Objectives: To identify the partial sequences of equine POMC, PC1, and PC2 mRNAs; and to 
determine whether the expression of POMC, PC1, and PC2 mRNAs in whole pituitary extracts, 
and POMC-protein in the cavernous sinus blood of horses are altered in PPID. 
Materials and Methods: Total RNA was extracted from the entire pituitary glands of 6 normal 
and 6 PPID affected horses. cDNA was generated and RT-PCR was used to generate sequences 
which were subsequently extracted, purified and sequenced. Nine internal control genes were 
screened for suitability for use in the pituitary gland. cDNA was amplified using primers based 
on predicted Equus caballus sequences for POMC, PC1 and PC2, and subjected to RT-qPCR to 
determine expression between normal and PPID horses. Commercial ELISAs (POMC, ACTH, 
CLIP) and a RIA (αMSH) were used to determine plasma concentrations in the ventral cavernous 
sinus blood. 
Results: Partial sequences obtained match the corresponding regions of predicted equine POMC, 
PC1 and PC2 sequences. The expression of POMC, PC1 and PC2 mRNAs were found 
upregulated in the pituitary of horses with PPID. Plasma ACTH and α-MSH were elevated, while 
CLIP was lower in PPID horses. 
Conclusions: There are distinct differences in gene and protein expression of POMC and its 
intermediates, and processing enzymes in PPID. This data provides evidence to support the 
notion that local, pituitary-specific inadequacies in prohormone processing likely contribute to 
equine PPID. 
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3.2 INTRODUCTION 
 
Equine pituitary pars intermedia dysfunction (PPID), also known as equine Cushing’s disease, is 
a common disease of horses older than 15 years. It is the most common endocrine disease of the 
equine species with reported prevalence between 14% and 30% in aged horses (McGowan et al. 
2013). Horses with PPID suffer significant morbidity and chronically poor welfare from myriad 
clinical signs. Hypertrichosis, chronic recurrent laminitis and redistribution of body fat occur 
frequently, as does increased susceptibility to opportunistic infections of the skin and respiratory 
tract. PPID is proposed to be a primary neurodegenerative disorder characterized by a lack of 
dopaminergic inhibition of the melanotrophs of the pars intermedia (Millington et al. 1988; 
McFarlane et al. 2005). In vitro and in vivo studies in rats and sheep have shown that in the 
absence of dopamine, hyperplasia and hypertrophy of the melanotroph cell line occur (Gehlert et 
al. 1988; Engler et al. 1990). In mice with dopamine type-2 (D2R) receptor deficiencies, the gene 
expression of proopiomelanocortin (POMC) and its associated prohormone convertases (PC1 
and PC2) are upregulated (Saiardi et al. 1988). This results in an overabundance of downstream 
POMC-peptides, such as adrenocorticotrophic hormone (ACTH) cleaved from POMC by PC1; 
and alpha-melanocyte stimulating hormone (α-MSH) and corticotrophin-like immune peptide 
(CLIP) cleaved from ACTH by PC2, being released into the systemic circulation. This theory is 
given additional support by the fact that clinical signs and endogenous ACTH levels normalize in 
the face of treatment with a dopamine agonist (pergolide mesylate). 
 
We hypothesized that PC1 and PC2 levels in the pituitary gland are altered in PPID, resulting in 
an abnormal relative abundance of POMC derived proteins. Our aims were to confirm the native 
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cDNA sequences of equine POMC, PC1 and PC2; to determine the most reliable internal control 
gene for use when quantifying mRNA expression of POMC, PC1 and PC2 in the pitutary; to 
quantify and compare the mRNA expression of POMC and PCs in normal and PPID horses; and 
to quantify the plasma concentrations of POMC, ACTH, α-MSH and CLIP in the blood from the 
ventral cavernous sinus of normal and PPID horses. 
 
3.3 MATERIALS AND METHODS 
3.3.1 ANIMALS 
 
The whole pituitary gland of 10 normal and 6 PPID horses, submitted to the Department of 
Veterinary Pathology at the Western College of Veterinary Medicine, University of 
Saskatchewan, were collected immediately post-mortem. The gland was diced into small pieces 
and snap frozen in liquid nitrogen. Samples were stored at -80° C until total RNA extraction. 
Normal horses comprised of 4 geldings, one stallion, and 5 mares with a mean age of 10.1 years. 
The PPID horse group, which exhibited the classical signs of disease (hypertrichosis, laminitis 
and fat redistribution), comprised of 2 geldings and 3 mares (1 sex was not recorded) with a 
mean age of 22 years. The age disparity between groups was a function of the age-related nature 
of PPID. 
 
An additional 6 normal horses and 6 PPID horses were used for ventral cavernous sinus blood 
collection. Normal horses (5 mares and 1 gelding) had a mean age of 12.2 years, whereas the 
horses exhibiting signs of PPID (5 mares and 1 gelding) had a mean age of 24.3 years. Horses 
were obtained by private donation to the research program, with signed, informed consent 
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provided by the owners. They were housed in an outside paddock with hay and water provided 
ad-libitum. Blood was collected from the ventral cavernous sinus of standing horses using 
techniques reported earlier (Irvine and Alexander 1987). Blood was placed into plastic tubes 
containing EDTA (1.8 mg/mL), stored on ice during the collection period and then centrifuged at 
4000 rpm for 15 minutes at 4° C. Plasma was collected and frozen at -80° C, for further hormone 
and PC measurements. 
 
3.3.2 TOTAL RNA EXTRACTION AND cDNA SYNTHESIS 
 
Total RNA was extracted from the whole pituitary samples using TRIzol RNA isolation reagenta. 
The entire pituitary gland was diced and mixed to prevent including just one region, 1 mL TRIzol 
was added to 1 mg of diced pituitary tissue samples, and homogenized by bead disruptionb and 
incubated in room temperature for 5 minutes. Phase separation was performed by adding 200 μL 
chloroform to each sample. Samples were mixed thoroughly, and centrifuged for 15 minutes at 
13000 rpm before the aqueous phase was transferred for RNA precipitation. Isopropanol (500 
μL) was added and centrifuged for 15 minutes at 13000 rpm. Pelleted RNA was washed with 1 
mL of 75% ethanol and dissolved in pure RNase free water. The purity of extracted RNA was 
assessed by optical density absorption ratio (OD 260/280 nm)c. One microgram of total RNA was 
used for cDNA synthesis using a commercial kitd as directed by the manufacturer. cDNA 
samples were stored at -20° C until RT-PCRs and RT-qPCRs. 
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3.3.3 PRIMERS 
 
Primers were designed using Primer-BlastTM from National Center for Biotechnology 
Information (NCBI)e. Equus caballus POMC (GenBank: XM_014731265.1), PC1 (GenBank: 
XM_001504608.4), and PC2 (GenBank: XM_001491591.5) primer sets were designed based on 
partial predicted sequences with the accession numbers listed above (Table 3.1). Primers were 
commercially synthesizedf, validated and optimized for high primer efficiency and annealing 
temperatures. Then, primers were used for Reverse Transcription-Polymerase Chain Reaction 
(RT-PCR) or Reverse Transcription-Quantitative PCRs (RT-qPCR). 
 
3.3.4 RT-PCR AND SEQUENCING 
 
RT-PCRs were carried out using 1 μL of cDNA, 50 μM dNTP’s, 10x PCR reaction mix, 2.5 mM 
MgCl2 and 0.5 μL taq DNA polymeraseg making total of 20 μL of reaction volume. PCR 
conditions were: initial denaturation for 5 minutes at 95° C followed by 35 cycles of denaturation 
at 95° C for 1 minute, annealing temperature (Table 3.1) and extension at 73° C for 1 minute, and 
a final extension of 73° C for 10 minutes. PCR products were electrophoresed on 1.5% agarose 
gel. The images of the gel were recorded under UV lighth. Bands of the expected size were 
excised from 1.5% agarose gel. Four bands, representing expected amplicons, were purifiedi and 
sent for sequencing (National Research Council, Canada). Sequences obtained were analyzed by 
NCBI and aligned to predicted equine POMC, PC1, and PC2 using NCBI nucleotide blast 
toolsj,k. A comparison of partial sequences from normal and PPID horses to determine whether 
differences in the critical (mature peptide or enzyme) sites of the sequences was performed. 
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Table 3.1 Sequences of primers, gene bank accession number, amplicon size, and annealing 
temperature used for RT-PCR and RT-qPCR. 
 
Gene Primer 
Accession No. 
GenBank 
Amplicon  Size 
(bp) 
Annealing 
Temperature 
(
°C) 
POMC 
F- CAAGATCGACCTCTCCGCTG* 
R- GGTCACTTCCACATGGGTGC* 
F- TCAGGCTTCTGTGGAAGT+ 
R- AAGTGGCCCATGACGTA+ 
XM_014731267.1 
313 
 
178 
60 
 
61 
PC1 
F- TGGGTTGCTAAATGCCAAAGC*+ 
R- ACAACCGACTTTCTCTCGCC*+ 
XM_001504608.4 300 60 
PC2 
F- TGTGGGGTCGGAGTAGCATA* 
R- CCGTCGATGCTGCTGACATT* 
F- CAACGATCCCTATCCGTA+ 
R- CGTCATAAATGGCTGGTC+ 
XM_001491591.5 
280 
168 
60 
 
60 
18S rRNA 
F- AACGACACTCTGGCATGCTAACT*+ 
R- CGCCACTTGTCCCTCTAAGAA*+ 
XM_001497064 98 60 
GAPDH 
F- AGAAGGAGAAAGGCCCTCAG+ 
R- GGAAACTGTGGAGGTCAGGA+ 
NM_001163856 87 56 
B2M 
F- GTGTTCCGAAGGTTCAGGTT+ 
R- ATTTCAATCTCAGGCGGATG+ 
NM_001082502 102 55 
ACTB 
F- CGACATCCGTAAGGACCTGT+ 
R- CAGGGCTGTGATCTCCTTCT+ 
NM_001081838 99 56 
GUSB 
F- GGGATTCGCACTGTGGCTGTCA+ 
R- CCAGTCAAAGCCCTTCCCTCGGA+ 
XM_001493514.2 116 62 
SDHA 
F- GCAGAAGAAGCCATTTGAGG+ 
R- CCTGTCGATTACGGGTCTGT+ 
XM_001490889.4 102 55 
YWHAZ 
F- TGTTGTAGGAGCCCGTAGGT+ 
R- ATTCTCGAGCCATCTGCTGT+ 
XM_001492988 94 60 
SLC36A2 
F- GCTTCTGCCACAGGCTTAAC+ 
R- CCGGCTTTGAGTCCATACAT+ 
XM_001501324.3 69 55 
Cyp19a1 
F-  GAGATGCCGTGGGAATTCTAGC+ 
R- ACGTTTCTCAGCCAAAAT+ 
NM_001081805 109 55 
*Used for RT-PCR, +Used for RT-qPCR 
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Once the sequences obtained, although partial, confirmed the predicted sequences, the same 
primers were used for RT-qPCRs. 
 
3.3.5 RT-QUANTATIVE PCR 
 
cDNAs were amplified by CFX connectl (Bio-Rad, Canada) using iQ SYBR green supermixm, 
and forward and reverse primers shown in Table 3.1. For each sample, RT-qPCR was run in 
duplicate and repeated again to ensure consistency. The thermal profile for all reactions was 5 
minutes at 95° C and 40 cycles of 10 seconds denaturation at 95° C, 30 seconds of optimum 
annealing temperature as shown in Table 3.1, and 10 seconds of final extension at 73° C. 
Specificity of amplified products in RT-qPCR assays were determined by analyzing the melting 
curve to differentiate the target amplicon from primer dimers and other nonspecific products. A 
single melt curve was observed for each primer set of all RT-qPCR reactions.  
 
Our extensive search in the literature for a suitable internal control gene that was validated for 
use in pituitary samples of horses was not successful. The Ct values of glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), 18S rRNA (18S), beta- 2-microglobulin (B2M), beta actin 
(ACTB), succinate dehydrogenase complex (SDHA), beta glucoronidase (GUSB), and tyrosine 
3-monooxygenase/tryptophan 5-monooxygenase activation protein (YWHAZ) were examined. 
These genes were had previously been validated for use in equine reproductive tissues (Klein et 
al. 2011). Based on the results of this validation, the Ct values of POMC, PC1, and PC2 were 
normalized to YWHAZ, which had been chosen as the housekeeping gene. Relative mRNA 
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expressions of genes of interest were determined according to Livak and Schmittegen (2001). All 
reagents were stored under desired condition until use. 
 
3.3.6 HORMONE MEASUREMENTS 
 
Plasma ACTH concentrations were measured using a commercial sandwich assayn,o. The plasma 
samples and test controlsp, were thawed and maintained on ice until analysis. Intra-assay 
coefficients of variation were 4.61% to 0.33% for low and high control sera with mean ACTH 
concentrations of 31.45 or 460 pg/mL, respectively. The manufacturer’s stated analytical 
sensitivity, lower limit of detection, was 9 pg/mL. Competitive sandwich enzyme-linked 
immunosorbent assays (ELISAs) were performed for POMC (manufacturer’s stated analytical 
sensitivity was 0.1 ng/mL, intra-assay coefficients of variation were 11.19% to 11.48% for 
control sera with mean POMC concentrations of 0.39 or 8.08 ng/mL, respectively), and CLIP 
(manufacturer’s stated analytical sensitivity was 5.0 pg/mL; intra-assay coefficients of variation 
were 5.24% to 5.55% for control sera with mean CLIP concentrations of 57.9 or 483.7 pg/mL, 
respectively) following manufacturers guidelinesq,r. A commercial RIAs was used for the 
determination of α-MSH concentrations (manufacturer’s stated analytical sensitivity was 5 
pg/mL (3 pmol/L), intra-assay coefficients of variation were 0.81% to 5.52% for control sera 
with mean α-MSH concentrations of 20.5 pg/mL or 125.3 pg/mL (12.3 or 75.2 pmol/L), 
respectively). Manufacturer’s guidelines for the ACTH assay stated no cross-reactivity to αMSH, 
but a 13-15% cross-reactivity to ACTH (18-39). Information contained with the αMSH RIA 
stated no cross-reactivity to ACTH and guidelines for the CLIP ELISA stated that “no significant 
cross-reactivity or interference between this analyte and analogues is observed”.  
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3.3.7 STATISTICAL ANALYSIS 
 
All values were reported as means ± SEM. Statistical analysis was performed using PRISM 5.0t 
and SPSSu. Comparisons between groups were made using Student’s t-test (and a Mann-Whitney 
U test where appropriate. P values < 0.05 were considered statistically significant. 
 
3.4 RESULTS 
 
Partial mRNA sequences of POMC, PC1 and PC2 were obtained and found to be identical to the 
predicted equine sequences used to design the primers. It also confirmed the hormone-encoding 
region in the native equine POMC (GenBank Accession number: KY275178), and sequences of 
PC1 (GenBank Accession number: KY275179), and PC2 (GenBank Accession number: 
KY275180) mRNA sequences. Equus POMC partial nucleotide sequence exhibited high 
similarity to corresponding regions in the predicted horse (Equus caballus 95%), and human 
(Homo sapiens, 85%) POMC nucleotide sequences. The partial amino acid sequences of POMC, 
αMSH and CLIP were also highly similar to predicted horse (Equus caballus 90%, 69.2%, and 
91.9% respectively) and human (Homo sapiens, 80%; 69.2% αMSH; 10% CLIP) sequences 
(Figure 3.1A). Additionally, PC1 (Figure 3.1B) and PC2 (Figure 3.1C) partial sequences showed 
very high similarity to predicted horse (Equus caballus, 99% and 98%, respectively) and human 
(Homo sapiens, 98%, 96%, respectively) PC1 and PC2 nucleotide sequences. Horse PC1 and 
PC2 partial amino acid sequences were found to be identical to predicted horse (Equus caballus 
99% and 100%, respectively) and human (98%, 100%, respectively) sequences. When comparing 
the amino acids sequences, we did not find any differences in POMC, PC1 or PC2
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Figure 3.1A Equine POMC partial amino acid sequence compared to predicted Equus caballus 
and Homo sapiens sequences. Red arrow denotes the cleavage point within POMC for ACTH 
(the first 13 amino acids of which become αMSH (red line), and the latter amino acids (14-39)) 
subsequently become CLIP (red arrow with dashed end). 
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Figure 3.1B Equine PC1 partial amino acid sequence compared to predicted Equus caballus and 
Homo sapiens sequences.  
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Figure 3.1C Equine PC2 partial amino acid sequence compared to predicted Equus caballus and 
Homo sapiens sequences. 
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sequences between normal and PPID horses. 
 
Of the 9 genes tested as internal control genes (Figure 3.2A), only 18S rRNA (Figure 3.2B), and 
YWHAZ (Figure 3.2C) genes were found to be stable, and provided consistent Ct values in 
control and PPID groups. Other genes were not stable, provided inconsistent Ct values and were 
considered not reliable for use. 
 
POMC, PC1 and PC2 mRNAs were expressed in the equine pituitary gland tissue (Figure 3.3A). 
POMC (4.8 fold increase, p = 0.0083), PC1 (5.45 fold increase, p = 0.0007), and PC2 (5.27 fold 
increase, p = 0.011) mRNAs were significantly upregulated in the pituitary gland of horses with 
PPID (n = 6), when compared to normal horses (Figure 3.3B, C, and D, n = 10). There was no 
significant difference between the upregulation of PC1 and PC2 (p = 0.11) in PPID horses. 
 
There were no differences in POMC plasma concentrations between normal (n = 6) and PPID 
horses (n = 6, p = 0.68, Figure 3.4A). ACTH (p = 0.0005, Figure 3.4B) and α-MSH (p = 0.004, 
Figure 3.4C) plasma concentrations were significantly higher in PPID horses whereas CLIP (p = 
0.025, Figure 3.4D) concentrations were significantly lower in PPID horses. 
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Figure 3.2A Cycle threshold (Ct) values for all 9 internal control genes in the equine pituitary 
gland. Bars denote mean values (+/- SEM). 
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Figure 3.2B Cycle threshold (Ct) values for the mRNA expression of 18S rRNA in the pituitary 
gland of normal (n = 10) and PPID (n = 6) horses. Bars denote mean values (+/- SEM). 
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Figure 3.2C Cycle threshold (Ct) values for the mRNA expression of YWHAZ in the pituitary 
gland of normal (n = 10) and PPID (n = 6) horses. Bars denote mean values (+/- SEM). 
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Figure 3.3A A RT-PCR gel electrophoresis image showing the expression of equine POMC 
(178bp), PC1 (300bp) and PC2 (168bp) in the pituitary gland. NC denotes no-template control 
for the peptide to the left of the column. 
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Figure 3.3B POMC mRNA expression in the equine pituitary gland tissue from normal (n = 10) 
and PPID (n = 6) horses. Data are normalized to the YWHAZ house-keeping (HK) gene. Bars 
denote mean values (+/- SEM). ** = p < 0.01. 
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Figure 3.3C PC1 mRNA expression in the equine pituitary gland tissue from normal (n = 10) 
and PPID (n = 6) horses. Data are normalized to the YWHAZ house-keeping (HK) gene. Bars 
denote mean values (+/- SEM). *** = p < 0.001. 
 
 
 102  
Figure 3.3D PC2 mRNA expression in the equine pituitary gland tissue from normal (n = 10) 
and PPID (n = 6) horses. Data are normalized to the YWHAZ house-keeping (HK) gene. Bars 
denote mean values (+/- SEM). ** = p < 0.01. 
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Figure 3.4A Plasma concentrations of POMC in the plasma of ventral cavernous sinus blood of 
normal (n = 6) and PPID (n = 6) horses. Bars denote mean values (+/- SEM). 
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Figure 3.4B Plasma concentrations of ACTH in the plasma of ventral cavernous sinus blood of 
normal (n = 6) and PPID (n = 6) horses. Bars denote mean values (+/- SEM). *** = p < 0.001. 
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Figure 3.4C Plasma concentrations of αMSH in the plasma of ventral cavernous sinus blood of 
normal (n = 6) and PPID (n = 6) horses. Bars denote mean values (+/- SEM). *** = p < 0.001. 
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Figure 3.4D Plasma concentrations of CLIP in the plasma of ventral cavernous sinus blood of 
normal (n = 6) and PPID (n = 6) horses. Bars denote mean values (+/- SEM). * = p < 0.05. 
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3.5 DISCUSSION 
 
This study partially confirmed the predicted equine POMC, PC1 and PC2 mRNA sequences, and 
found the expression of all three transcripts in the equine pituitary. Our sequencing data, 
although only partial, matched that of the predicted sequences of all three genes. Additionally, 
there were no key differences in the amino acid sequence of hormones encoded in POMC, or 
PC1 and PC2 between normal and PPID horses. These findings are interesting because there is 
strong evidence suggesting that a significant portion of the elevated endogenous ACTH in PPID 
horses is likely not bioavailable (Orth et al. 1982; Cordero et al. 2012). A mutation in the POMC 
gene was reported in humans, resulting in immunologically active, but biologically inactive 
ACTH (Samuels et al. 2013).  
 
This mutation resulted in an ACTH analogue that could not bind to the M2R receptor on the 
adrenal gland. Our findings that the mRNA sequences of POMC, and the amino acid sequence of 
ACTH, did not differ between normal and PPID horses suggests that lack of ACTH bioactivity in 
horses is possibly not associated with a nucleotide polymorphism in the encoding gene. 
Combined with the clinical and laboratory evidence that treatment with a D2R-agonist 
normalizes endogenous ACTH levels, and the clinical signs of disease, our findings would 
suggest that the lack of ACTH bioactivity in PPID horses is more likely associated with post-
translational modification of the nascent ACTH, downregulation of the M2R receptor on the 
adrenal gland, or some other yet unidentified mechanism. Multiple candidate genes were 
assessed for use as internal control genes in the equine pituitary gland. The results showing that 
both 18S rRNA and YWHAZ could be used as an internal control/house-keeping gene is 
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significant because this information has not previously been reported. The reduced variability in 
the expression of the latter gene resulted in its subsequent use in our study. 
 
Our study found that POMC, PC1 and PC2 mRNA expression was elevated in the pituitary gland 
of PPID horses. Although only gene expression was studied here, this supports the mechanistic 
theory behind dopamine-deficient elevations in plasma ACTH concentrations extrapolated from 
murine studies (Saiardi et al. 1998). While both PC1 and PC2 mRNA expression increased in 
PPID horses, our results did not show the differential upregulation noted in D2R deficient mice, 
wherein PC1 increased in activity by 4 to 5 times, whereas that of PC2 increased by only 2 to 3 
times (Saiardi et al. 1998). There are several possible explanations. Firstly, while mammalian 
hormone mechanisms are typically conserved, species specific differences do exist. Secondly, the 
murine studies that postulated a lack of dopamine, used type-2 dopamine receptor deficient D2R 
knock-out mice. These mice do not actually suffer from a true dopamine-deficiency. It is possible 
that differential receptor binding may have altered the relative upregulation of the prohormone 
convertase sub-types. Finally, our method of whole gland extraction precluded cellular 
localization of the PC enzymes. It is possible that differential upregulation occurred in multiple 
areas of the gland with the overall result that there was not a difference between PC1 and PC2. 
Had tissue been removed from specific pars intermedia or pars distalis regions, it is possible that 
differential upregulation in the face of PPID may have been revealed. 
  
There were no differences in the concentration of POMC within the plasma of cerebral blood 
collected from the ventral cavernous sinus between PPID horses and control horses. This was not 
surprising because despite increased POMC mRNA expression, the protein would have been 
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cleaved into the downstream, smaller peptides, including ACTH, α-MSH and CLIP before 
release into the ventral cavernous sinus. Our findings concur with previously reported literature 
in that there were significant elevations in ACTH and α-MSH in PPID horses compared to 
control horses (Couëtil et al. 1996; Lee et al. 2010; Beech et al. 2013; McGowan et al. 2013). 
Interestingly, the increase in α-MSH was not mirrored by a concomitant rise in the concentration 
of CLIP. This was likely a function of the assay (which was not validated in this study) as initial 
analysis of α-MSH using an equine specific ELISA kit showed no elevation of hormone 
concentration in PPID animals (data not shown). Repeating the analysis using the 
radioimmunoassay as used by other investigators (McFarlane et al. 2006; Cordero et al. 2012; 
McGowan et al. 2013) resulted in the finding that a significant elevations in α-MSH occurred in 
PPID horses. It is possible that a CLIP-specific RIA would have demonstrated concomitant 
increases in this POMC-peptide, especially given the fact that α-MSH and CLIP are cleaved from 
ACTH.  
 
In conclusion, the series of studies reported here supported the hypothesis that PC1 and PC2 in 
the equine pituitary gland is upregulated in PPID. This is associated with an abnormal abundance 
of POMC derived proteins being released into the blood of the ventral cavernous sinus, and then 
into the blood of the systemic circulation. We only determined partial sequences of POMC, PC1 
and PC2. In addition, tissue expression of these proteins was not determined. Despite these 
limitations, our results conclude that upregulation of PC1 and PC2 occur in PPID horses which 
cleave a normal POMC polypeptide, resulting in elevated concentrations of POMC-derived 
peptides in the diseased state. Future research should focus on more in depth studies of the 
endocrine milieu during various stages of PPID.  
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 Footnotes: 
a TRIzol. Invitrogen Inc. Canada. 
b TissueLyser, Qigen, Canada 
c Nanodrop. ND-2000c, Thermo Scientific Inc. Canada 
d iScript cDNA. Bio-Rad. Canada. 
e Primer-BlastTM: www.ncbi.nlm.nih.gov/tools/primer-blast/. 
f IDT Inc. Canada. 
g Taq DNA polymerase. Invitrogen Inc. Canada 
h Gel DocTM, EZ Imager, Bio-Rad, Canada. 
i QIAquick Gel extraction kit. Qiagen Inc. Canada 
j NCBI nucleotide blast. https://blast.ncbi.nlm.nih.gov/Blast. 
k http://www.ebi.ac.uk 
l CFX Connect, Bio-Rad, Canada 
m iQSYBR green supermix. Bio-Rad, Canada 
n Siemens ACTH kit, Siemens Canada, Oakville, ON, Canada 
o Immulite 1000 Chemiluminescent System, Siemens Canada, Oakville, ON, Canada 
p Bi-level ACTH control module, Siemens Canada Oakville, ON, Canada 
q POMC- MBS012413, MyBioSource Inc., San Diego, CA, USA 
r CLIP-MBS088236, MyBioSource Inc., San Diego, CA, USA 
s Euria –α-MSH, Euro Diagnostica AB, Malmö, Sweden 
t PRISM 5.0, GraphPad Software, Inc. La Jolla, CA USA 
u SPSS version 21, IBM Canada Ltd, Markham, ON, Canada 
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CHAPTER 4 
 
INTRAARTERIAL INJECTION OF IODINATED CONTRAST MEDIUM FOR CONTRAST 
ENHANCED COMPUTED TOMOGRAPHY OF THE EQUINE HEAD 
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CHAPTER 4 
TRANSITION PAGE 
Intraarterial injection of iodinated contrast medium for contrast enhanced 
computed tomography of the equine head. 
This chapter presents the methodology for contrast-enhanced computed tomography 
using intraarterially delivered contrast material. This has the benefit of allowing the 
delineation of the margins of the pituitary gland and, additionally, being significantly 
more cost-effective than a large intravenous dose of contrast agent which suffers from 
volume depletion. 
This work is important in that it allows a determination of pituitary gland size, which 
may be a helpful adjunct test in the ante-mortem diagnosis of pituitary pars intermedia 
dysfunction. This may allow earlier diagnosis of this condition to be made, resulting in 
earlier treatment and an improvement in the welfare of the aged horse. 
Copyright statement: Chapter 4 has been published and is reproduced here with the 
permission of the copyright owner (Journal of Veterinary Radiology and Ultrasound – 
John Wiley and Sons, Inc.) 
Full citation: Carmalt JL and Montgomery J. Intraarterial injection of iodinated contrast 
medium for contrast enhanced computed tomography of the equine head. Vet Radiol 
Ultrasound. 2015; 56(4): 384-390. doi: 10.1111/vru.12252 
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Author contributions: Carmalt conceptualized the experiment, performed the surgical 
approach to the carotid arteries and the ultrasound guided intra-arterial contrast agent 
delivery. He also read the CT images, performed measurements of the pituitary glands 
and regions of interest and statistical interpretation. Montgomery provided the expertise 
as to the time-of-flight technique. Carmalt wrote the paper with editorial input from 
Montgomery. 
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4.1 ABSTRACT 
 
Objectives:  To determine whether low-volume intraarterial administration of contrast 
medium would result in an equivalent image quality and tissue attenuation versus high-
volume intravenous bolus administration for enhanced computed tomography (CT) of the 
equine head. 
Materials and Methods: A prospective cross-over experimental design was used in 6 
horses. After anesthetic induction, the right carotid artery was exposed surgically and 
catheterized. Four CT scans of the cranium were performed for each horse: baseline, 
immediately following intraarterial contrast injection, 5-minutes post injection (return to 
baseline) and after intravenous contrast administration. Soft tissue attenuation in pre-
determined regions of interest (ROI); and length, width and height measurements of the 
pituitary gland were recorded at each time point. Horses were euthanased and pituitary 
gland measurements were repeated post-mortem.  
Results: Margins of the pituitary gland could not be accurately delineated without 
contrast enhancement. Intraarterial and intravenous administration of contrast medium 
resulted in significantly greater soft tissue enhancement of some brain ROI and the 
pituitary gland versus baseline values. Pituitary gland measurements made on post-
contrast CT images did not differ from those obtained during postmortem examination. 
Conclusions: Low-dose intraarterial administration of contrast material in the equine 
head resulted in comparable soft tissue enhancement versus high-volume intravenous 
administration.
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4.2 INTRODUCTION 
 
Computed tomography (CT) is a widely used advanced imaging modality for diagnosis of 
suspected cranial lesions and surgical planning in the equine head (Puchalski et al. 2010). 
While superior to CT for evaluation of soft tissues, disadvantages of magnetic resonance 
imaging (MRI) for the equine head include less availability, longer anesthesia times, and 
greater expense (Holmes 2013).  While more available, disadvantages of radiographic 
cerebral angiography for the equine head include high contrast medium dosages and 
costs. There are few publications describing the use of contrast agent administered via an 
intravenous (IV) injection for enhanced computed tomography of the equine head and 
dosages vary widely. One report examined the brain after traumatic head injury and 
another assessed the long-term (6 months) effect of pergolide treatment on pituitary gland 
size (Lacombe et al. 2010; Pease et al. 2011). Both of these report high-volume IV 
injection of iodinated contrast medium: Pease et al. – 250 mL of 370 mgI/mL; Lacombe 
et al. – approximately 300 mL of 350 mgI/mL.  A third report discussed the use of 
contrast-enhanced CT as a potentially useful tool in the assessment of the equine head, 
but did not report the dose to administer, or discuss timing of the scan required to acquire 
contrast-enhanced images of the head (Kinns and Pease 2009). A previous cadaver study 
used contrast-enhanced CT to describe effects of CT slice thickness on equine pituitary 
gland measurements and reported a dosage of 60 mL administered by bolus injection IV 
immediately ante-mortem (McKlveen et al. 2003) and a single abstract reported the use of 
intraarterial (IA) contrast administration for CT the equine head (Bergman et al. 2012).   
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Disadvantages of IV contrast administration center around the large volume of contrast 
medium required in a horse.  This leads to a high cost of contrast material, and an 
extended duration of the injection time.  With a long injection time there is marked 
dilution of the contrast medium within the vascular space and decreased contrast 
enhancement.  When administered IA and targeted to a specific region such as the head, a 
lower volume of contrast medium can be used, as has been demonstrated in the equine 
distal limb (Puchalski et al. 2007). This would help reduce the cost associated with 
contrast medium administration, and may provide greater contrast resolution when 
compared to the previously reported high-volume IV contrast techniques. An IA contrast 
injection technique may also be helpful for  comparing characteristics of intracranial 
structures during arterial and venous phases.   
 
The objectives of the current study were to determine whether a low-volume IA bolus of 
contrast medium would result in equivalent image quality and tissue attenuation on CT 
examination versus a high-volume IV bolus technique; and whether contrast 
administration allowed greater delineation of the hypophyseal margins such that the 
accuracy of size measurements of this intracranial structure would be improved above 
those obtained without the use of contrast material. The hypothesis was that low-volume 
IA contrast administration would prove to be equal, both in terms of image quality and 
contrast-enhancement; and would result in comparable hypophyseal margin delineation 
with the high-volume IV technique. 
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4.3 MATERIALS AND METHODS 
 
This work was approved by the University of Saskatchewan Animal Research Ethics 
Board and adhered to the Canadian Council on Animal Care guidelines for humane 
animal use. 
 
Six horses, weighing between 475 kgs and 550 kgs were recruited.  Included horses were 
either surrendered by their owner or were destined for slaughter. Each horse had the 
jugular furrows clipped of hair prior to IV jugular catheterization of the right jugular vein. 
Horses were then pre-medicated using 1.1 mg/kg xylazinea and anesthesia was induced 
with 2.2 mg/kg ketamineb both administered IV. Anesthesia was maintained with IV 
“triple-drip” (xylazine, ketamine and guaiphenesin combination) with the addition of 
intranasal oxygen for the duration of the procedure. 
 
Horses were positioned in left lateral recumbency and a 10 cm surgical incision was made 
in the right jugular furrow, immediately superficial to the jugular vein. The right common 
carotid artery was isolated from the vagosympathetic trunk and catheterized with a 14 G 
3.5” catheterc. A Penrose drain was placed around the isolated artery to facilitate later 
identification and the artery allowed to return into the incision. A sterile towel was placed 
over the incision and the horse moved to the computed tomography suite. In Horse 6, a 
second common carotid artery catheterization was performed percutaneously using 
ultrasound guidance to determine whether surgical intervention was necessary to perform 
intraarterial contrast administration.   
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The horses were placed in left lateral recumbency on the CT table and positioned at the 
start of the IA scan with the table advanced as far forward as possible (i.e., such that the 
direction of the scan acquisition would follow the direction of blood flow). After the 
mean arterial pressure (MAP) of the horse was stabilized at 70 mmHg, a pre-contrast CT 
of the cranium was performed using a standard protocold. Technical factors included a 
helical acquisition with pitch of 0.94, slice width 1 mm, tube rotation time of 0.75 
seconds, 135 kVp, 380 mA, and 512 x 512 image matrix.  All scans were reconstructed 
with a soft tissue and bone algorithm.  The rostral limit of the scan was immediately 
rostral to the cribriform plate extending as far caudal on the neck as the size of the horse 
would permit in terms of entry into the CT gantry, generally to the level of the second 
cervical vertebrae. This was followed by the administration of 44 mL of 240 mgI/mL 
Iohexole delivered into the carotid artery with a pressure injectorf at a rate of 4 mL/s and 
pressure limited to a maximum of 325 psi. A scanning protocol to include arterial and 
venous phases of contrast enhancement was performed.  The initial scan was started 5 
seconds after the initiation of the injection such that 20 mL of the total 44 mL volume of 
the injection had been infused with continual injection throughout the arterial phase scan.  
The length of the scan varied between horses as the size of the horses and subsequent area 
included in the scan differed between animals. 
 
After the IA post-contrast CT scan was performed, there was a delay of 5 minutes prior to 
an additional scan of the same region placing ROI in predetermined locations to verify 
that tissues had returned to their pre-contrast (baseline) administration attenuation levels, 
as determined in the pre-contrast CT. 
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Once confirmed, the high-volume IV angiographic scan was performed using manual 
injection of 240 mL Iohexol 350 mgI/mL (due to the large volume being greater than the 
capacity of the pressure injector) via the jugular vein catheter. The start time for the scan 
after the IV injection was 1 minute, allowing for delivery of the contrast agent to the 
cerebrum.  
 
Objective assessment of soft tissue contrast enhancement was performed by measuring 
the Hounsfield units (HU) within an ROI at multiple locations in the images which were 
standardized for all horses in an axial slice in a soft tissue window at the level of the 
middle of the pituitary gland: 1) the center of the pituitary gland, 2) right cerebrum, 3) left 
cerebrum, 4) right temporalis muscle, 5) left temporalis muscle, 6) right digastricus 
muscle, 7) left digastricus muscle, 8) right jugular vein, and 9) left jugular vein. The sizes 
of the ROI were standardized within each patient and, in positioning the ROI every effort 
was made to locate them at a corresponding position between patients.  Subjective 
assessment of image quality was also recorded. The region of the hypophysis was 
identified and the margins delineated, if possible. The images were viewed in a window 
width of 350, and window level of 35. The length (measured in a sagittal plane 
reconstruction), width and height of the gland was measured and recorded in the pre-
contrast, as well as in both the IV and IA injection post-contrast sequences. 
 
After the completion of the diagnostic procedure the horses were euthanised using an IV 
overdose of barbiturate. Heads were disarticulated and the crania opened. The brain was 
removed leaving the hypophysis in-situ. This was carefully elevated from the underlying 
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basisphenoid bone and the length, width and height were measured using calipers. All 
data were subsequently entered into a Windows-based spreadsheet programg and statistics 
performed using a commercial statistical software packageh. 
 
Linear regression generalized estimating equations assuming a normal distribution and 
controlling for repeated observations on individual horses were used to examine the effect 
of potential risk factors on soft tissue attenuation (HU), before and after each of the 
contrast administration techniques (IA and IV). All potential risk factors (age, sex, 
location of ROI and method of contrast administration (baseline, IA, IV)) were initially 
screened using unconditional analysis and variables where the p-value of < 0.2 were 
submitted for consideration in building the final model (Dohoo et al. 2010). All final 
models were built using manual backwards elimination. Variables that were not 
significant were assessed as potential confounders. Risk factors were considered 
confounders if adding or removing the factor from the model changed the regression 
coefficient for another risk factor by more than 10% (Dohoo et al. 2010). Where 2 or 
more variables were significant, biologically plausible 2-way interactions were assessed 
with significant interactions retained in the final model (p < 0.05). All possible pairwise 
comparisons were examined for significant categorical interactions using a least 
significant difference adjustment for multiple comparisons. 
 
Comparisons of the measurements taken of the pituitary gland obtained at baseline, 
intraarterial or intravenous contrast enhancement were performed using an analysis of 
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variance with those obtained at post-mortem used as the definitive measurements. The 
level of significance was set at p < 0.05. 
 
4.4 RESULTS 
 
There were 3 mares and 3 geldings.  The mean age of horses was 21 years (SD +/- 5.97 
years, range 14 to 30 years). No significant alterations in MAP or anesthetic depth 
accompanied either method of contrast agent administration. There was no seizure-like 
activity noted during any of the procedures.  
 
Unconditional analyses of factors potentially affecting soft tissue attenuation are 
presented in Table 4.1. The final multivariable model is presented in Table 4.2. 
Univariable analysis indicated that sex, ROI location and the method of contrast 
administration affected soft tissue enhancement. Geldings had more soft tissue 
enhancement than mares (p < 0.001). The multivariable model included sex, location of 
ROI and method of contrast administration as well as interaction terms between ROI and 
method of contrast administration (p < 0.001) and between sex and ROI (p < 0.001). 
There was no interaction between method of contrast administration and sex, nor a 3-way 
interaction between the significant terms. The left jugular vein had significantly greater 
contrast enhancement with the IV (predicted mean HU 60.92 +/- SD 10.06) than the IA 
administration (32.85 +/- 5.92, p < 0.001) or baseline values (34.97 +/- 6.92, p < 0.001). 
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Table 4.1 Unconditional analysis of potential factors on soft tissue attenuation measured               
in Hounsfield units 
 
 
a  = Regression coefficient 
b ROI = Region of interest 
c MOCA = Method of contrast administration 
 
Potential Factor ßa 
95% Confidence Interval p-value 
Lower Upper  
     
Age (years) 0.32 - 0.21 0.85 0.23 
Sex (gelding versus mare) 8.09 4.72 11.45 < 0.001 
ROI (Overall)b < 0.001 
   ROI = Left jugular vein - 12.06 - 20.17 - 5.04 0.001 
   ROI = Right jugular vein - 7.86 - 17.12 1.41 0.10 
   ROI = Left digastricus muscle 1.10 - 6.09 8.30 0.76 
   ROI = Right digastricus muscle 2.45 - 5.93 10.78 0.57 
   ROI = Left temporalis muscle - 16.41 - 28.06 - 4.75 0.006 
   ROI = Right temporalis muscle - 5.85 - 15.25 4.27 0.24 
   ROI = Left cerebrum - 24.79 - 32.52 - 17.06 < 0.001 
   ROI = Right cerebrum - 26.73 - 35.79 - 17.68 < 0.001 
   ROI = Pituitary gland Reference Category 
MOCAc (Overall)    < 0.001 
   MOCA = Baseline versus IA - 7.11 - 11.25 - 2.97 0.001 
   MOCA = Baseline versus IV - 10.66 - 14.33 - 6.99 < 0.001 
   MOCA = IA versus IV - 3.55 -7.71 0.61 0.09 
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Table 4.2 Final multivariable model of factors affecting soft tissue attenuation measured               
in Hounsfield units. 
 
 
a  = Regression coefficient 
b ROI = Region of interest 
c MOCA = Method of contrast administration 
d Interaction term within the final model 
Factor ßa 
95% Confidence Interval p-value 
Lower Upper  
     
Sex = M 11.65 1.57 21.73 0.02 
Sex = F Reference Category 
ROIb = Left jugular vein - 0.70 - 14.17 12.78 0.92 
ROI  = Right jugular vein - 5.50 - 17.71 6.71 0.38 
ROI  = Left digastricus muscle 18.64 6.14 31.13 0.003 
ROI  = Right digastricus muscle 14.60 - 2.14 31.34 0.09 
ROI  = Left Temporalis muscle 1.89 - 8.56 12.34 0.72 
ROI  = Right Temporalis muscle 0.34 - 10.45 11.14 0.95 
ROI  = Left cerebrum - 13.58 - 24.29 - 2.87 0.01 
ROI  = Right cerebrum - 14.28 - 27.27 - 1.30 0.03 
ROI  = Pituitary gland Reference Category 
MOCAc =  IV 11.47 6.06 16.89 < 0.001 
MOCA  =  IA 26.02 5.52 46.51 0.01 
MOCA  =  Baseline Reference Category 
MOCA * ROId    < 0.001 
Sex * ROId    < 0.001 
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The right jugular vein contrast enhancement was greatly increased with both IV (61.46 
+/- 12.68 HU) and IA administration (50.38 +/- 23.24 HU) over baseline values (28.60 
+/- 6.20 HU), but only significantly greater with the IV administration (p < 0.001). Both 
administration methods resulted in significant contrast enhancement of the right 
digastricus muscle (IV = 57.59 +/- 3.44 HU; IA = 56.82 +/- 3.44 HU; baseline = 50.55 +/- 
4.56 HU, p < 0.001) and the pituitary gland (IV = 57.59 +/- 3.44 HU; IA = 56.82 +/- 3.44 
HU; baseline = 50.55 +/- 4.56 HU, p = 0.008), but no difference between the IV or IA 
methods (p = 0.62 and 0.07, respectively). 
 
There was a significant difference between male and female horses (with the male horses 
having the greater contrast enhancement) at the left (male = 50.89 +/- 2.9 HU; female = 
35.46 +/- 3.46 HU) and right (male = 51.78 +/- 11.6 HU; female = 36.58 +/- 6.14 HU) 
temporalis muscles, as well as the right cerebrum (male = 33.25 +/- 8.90 HU; female = 
22.08 +/- 6.76 HU; p < 0.001, 0.023 and 0.04 respectively) 
 
The lateral, rostral and caudal margins of the pituitary gland could not be accurately 
delineated without contrast enhancement (Figure 4.1). Following contrast administration 
(IV or IA) measurements were not significantly different from those obtained during 
postmortem examination (p > 0.13). There was no significant difference in the 
measurements obtained between methods of contrast administration. 
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Figure 4.1 Axial CT slices of the same horse at the same level of the pituitary gland. 
A) Pre-contrast administration, B) High-volume IV injection, C) Low-volume IA arterial 
phase, D) Low-volume IA venous phase. 
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4.5 DISCUSSION 
 
Results of this study show that the low-volume IA and high-volume IV techniques for 
contrast-enhanced computed tomography of the equine cerebrum are comparable. Initially 
the IA injection was to be 30 mL of 350 mgI/mL iohexol. This dose was chosen as it was 
within the range of reported volumes used in human cranial CT angiography (Takeyama 
et al. 2008; Takeyama et al. 2012; Li et al. 2013). During the initial scan we discovered 
that the use of the power injector and 350 mgI/mL contrast medium created significant 
artifact due to the tight bolus of contrast medium with very little dilution in the blood 
pool. This created streak and blooming artifacts.  Streak artifacts occur when large 
quantities of intravascular contrast medium are present, particularly when, as in the case 
here, the vessel into which the contrast is injected is in the imaging field.  Blooming 
artifact is the blurring of the vascular margins and apparent increase in the size of the 
vessel diameter due to non-diluted contrast medium within the vessel (Pollard and 
Puchalski 2013). The protocol was therefore modified to dilute the 350 mgI/mL contrast 
medium to 240 mgI/mL with the addition of sterile saline creating a total volume of 44 
mL which was injected IA. Interestingly, a recent abstract reports the use of 180 mL 
iodinated contrast medium, in each of the carotid arteries delivered simultaneously for 
contrast-enhanced CT of the head in horses with disease of the skull or brain (Bergman et 
al. 2012). No mention of artifact was documented. 
 
The IA contrast administration was followed, following a wash-out period, by an 
intravenous injection of 240 mL iohexol (350 mgI/mL). From an experimental model 
 130 
 
standpoint, the project would have been more robust if a 2 x 2 Latin square design had 
been followed. As such, the effect of sequence of treatment (IA followed by IV) cannot 
be separated from the effect of treatment (i.e., the difference between treatments).  The 
order of the different methods of contrast delivery were not randomized between horses 
as the low-volume of contrast medium was expected to wash out rapidly from the soft 
tissues and the authors desired to minimize the duration of the anesthetic procedure.  
Given that in humans, the half-life for non-ionic iodinated contrast medium excretion has 
been reported to be 110 minutes (Krause et al. 1994) we expected that the time required 
for the soft tissues to return to their baseline, pre-contrast administration attenuation 
values, would have been significantly increased if the high-volume intravenous contrast 
injection had been administered first. Further work is required to determine whether our 
concerns were justified.   
 
Subjectively, the IA injection of contrast medium resulted in impressive ipsilateral 
contrast enhancement within the cranium. Statistically, however, when controlling for 
horse and sex, measurements of soft tissue attenuation were not greater than baseline. 
There was also no significant difference (p = 0.34, data not shown) between right 
(ipsilateral) and left (contralateral) cerebrae. This was also the fact with the high-volume 
IV contrast administration. Both methods of contrast administration allowed excellent 
visibility and delineation of the margins of the pituitary gland, especially in the venous 
phase of the IA injection allowing for accurate measurements of the gland, confirming a 
previous report (Pease et al. 2011). The lack of ipsilateral contrast enhancement with IA 
contrast administration was likely due to a lack of statistical power. However, in cases 
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where neurological symptoms exist that are not clearly defined, bilateral, concurrent IA 
contrast administration may be necessary, as has been previously reported (Bergman et al. 
2012).  
 
The effect of sex was unexpected and it is difficult for the authors to draw any definitive 
conclusions from these findings. It is possible that the males had an increased temporalis 
muscle mass which, in turn, required greater vascularization, but this is pure conjecture. 
We have no explanation for the significantly increased soft tissue attenuation of the right 
cerebrum, which was noted in the baseline measurements as well as after contrast 
administration. It is possible that pathological differences in this region were missed due 
to the fact that no histological examination was made of this region of the brain. 
However, it is more likely that low numbers of each sex are playing a role in these 
findings.  
  
We were able to successfully perform low-dose IA contrast-enhanced CT of the equine 
head.  The cut-down method was chosen in this study so that complete insertion of the 
catheter was achieved in every case. This allowed standardization of the IA method of 
contrast administration.  
 
In clinical practice, the ultrasound-guided percutaneous route would be used. Our 
experience generated from a single horse, did not show a difference in the contrast 
enhancement of the soft tissue structures achieved with this, compared to the cut down 
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method of accessing the carotid artery.  Additional prospective research assessing 
potential complications of percutaneous catheterization of the carotid artery is needed. 
 
Additional research is needed to optimize the scan parameters for different sized horses 
which could alter the length of the scan time and, therefore, the timing of the arterial and 
venous phases in the head, but that was beyond the focus and financial constraints of the 
current study. Clinical applications of this technique include any CT study in which 
contrast enhancement of intra-cranial structures or CT angiography is necessary. As an 
example, evaluation of the pituitary gland as an adjunct diagnostic test for pituitary pars 
intermedia dysfunction, to assess the impact of treatment (Pease et al. 2011), or to guide 
local therapy using low, rather than high-volume contrast enhancement may allow 
repeated scans in a single session without being cost-prohibitive.  
 
Horses in this study were not recovered from anesthesia. For this reason, the effect of IA 
administration of contrast material could not be determined. The use of ionic iodinated 
contrast material in the horse has been reported to cause reactions directly attributable to 
the material in 9% of cases (Pollard and Puchalski 2011). These authors report that no 
horse suffered severe systemic shock or had an anaphylactoid response as a result of these 
agents which were delivered into the distal extremities in all cases. The current authors 
are unaware of any reports of complications associated with intraarterial administration of 
non-ionic iodinated contrast agents (as used in this study) in the horse and this method of 
delivery is a commonly employed technique in the surgical treatment of equine guttural 
pouch mycosis (Freeman and Hardy 2012; Colles and Cook 1983). 
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In conclusion, we demonstrated that an IA injection can be used with a much lower 
volume of contrast medium with equal contrast enhancement of the cerebrum as an IV 
contrast medium injection of a much higher volume. Neither method significantly 
increased the soft tissue attenuation of the musculature of the equine head. Accurate 
measurement of the size of the equine pituitary gland can be performed using contrast 
enhancement with either delivery method. 
 
Footnotes: 
a Xylamax, Bimeda, Cambridge, ON, Canada 
b Vetalar, Bioniche, Belleville, ON, Canada 
c Angiocath, Becton Dickinson, Mississauga, ON. Canada 
d Toshiba Aquilion 16, Toshiba Medical Systems, Markham, Ontario 
e Omnipaque, GE Healthcare Canada, Inc., Mississauga, Ontario 
f Medrad Stellant Sx, Bayer HealthCare, Medrad, Inc. Indianola, PA 
g Microsoft Excel, Microsoft Canada Inc, Mississauga, ON, Canada 
h SPSS, IBM Canada Ltd, Markham, ON, Canada 
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CHAPTER 5 
 
EFFECTS OF ANESTHESIA WITH ISOFLURANE ON PLASMA 
CONCENTRATIONS OF ADRENOCORTICOTROPHIC HORMONE IN SAMPLES 
OBTAINED FROM THE CAVERNOUS SINUS AND JUGULAR VEIN OF HORSES 
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CHAPTER 5 
TRANSITION PAGE 
Effects of anesthesia with isoflurane on plasma concentrations of 
adrenocorticotrophic hormone in samples obtained from the cavernous sinus and 
jugular vein of horses. 
This chapter presents the effect of general anesthesia on concentrations and pulsatility of 
ACTH in ventral cavernous sinus (pituitary effluent) blood. Determining this is an 
important step in the application of the surgical technique to treatment of PPID. 
This work is important as it allows for the objective, real-time measurement of any 
change in endogenous ACTH production bought about by the manipulation of the 
pituitary gland. These changes may be used in surgery to determine the degree of 
selective surgical ablation of the pituitary gland in PPID horses. 
This work represents four important facets of research. Firstly, it is a proof of principle; 
secondly, it has intrinsic heuristic value; thirdly, the results are in contrast with those 
published elsewhere and finally, this technique may have application as a measure of 
stress in hospitalized and anesthetized equine patients.  
Copyright statement: Chapter 5 has been published and is reproduced here with the 
permission of the copyright owner (American Journal of Veterinary Research – American 
Veterinary Medical Association) 
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Full citation: Carmalt JL, Schott II HC, van der Kolk J and Duke T. Effects of anesthesia 
with isoflurane on plasma concentrations of adrenocorticotrophic hormone in samples 
obtained from the cavernous sinus and jugular vein of horses. Am J Vet Res 2016; 77: 
730-737. 
Author contributions: Carmalt performed the catheterizations, blood collections and 
sample preparations. Duke performed the anesthesia. Schott and van der Kolk provided 
support during the experimental design phase. Van der Kolk performed the auto-
deconvolution statistics while Carmalt performed all other statistical interpretation. 
Carmalt wrote the paper and all other authors contributed to the editing of the manuscript.
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5.1 ABSTRACT 
 
Objective: To determine the effect of general anesthesia on concentrations and pulsatility 
of adrenocorticotrophic hormone (ACTH) in cavernous sinus and peripheral plasma. 
Materials and Methods: Cavernous sinus blood was sampled via an indwelling catheter 
every 5 minutes for 1 hour, while peripheral blood was sampled at 0, 30 and 60 minutes. 
The next day, horses were placed under general anesthesia and 1 hour after induction, the 
same blood sampling protocol was repeated. ACTH concentrations were quantified using 
a commercially available sandwich assay. Generalized estimating equations controlling 
for individual horse, and an expressly automated deconvolution algorithm, were used to 
determine the effect of general anesthesia on plasma ACTH concentrations and 
pulsatility, respectively.  
Results: General anesthesia significantly reduced ACTH concentration in the cavernous 
sinus blood, as well as the number of secretion peaks. 
Conclusions: An overall reduction in mean plasma concentration of equine ACTH under 
anesthesia indicates that if partial-ablation of the pituitary gland in-situ is successful for 
treatment of pituitary pars intermedia dysfunction, the expected reduction in cavernous 
sinus ACTH concentration following ablation would have to be interpreted in light of the 
effects of general anesthesia.   
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5.2 INTRODUCTION 
 
Adrenocorticotrophic hormone (ACTH) is produced both in the pars distalis and pars 
intermedia of the equine pituitary gland. The hormone stimulates the adrenal gland to 
synthesize and release cortisol into the blood which then acts on the hypothalamus and 
pituitary gland in a negative feedback manner to manage overall circulating 
concentrations of this stress hormone to maintain homeostasis under different conditions 
(Alexander et al. 1996). 
 
Pituitary pars intermedia dysfunction (PPID) or equine Cushing’s disease is a common 
disease of older horses. There is mounting evidence that PPID develops as a consequence 
of the progressive loss of hypothalamic dopaminergic innervation to the pars intermedia, 
leading to hyperplasia and hypertrophy of the pars intermedia melanotrophs (Millington 
et al. 1998; McFarlane 2011). Pars intermedia melanotrophs produce pro-
opiomelanocortin (POMC), a 241 amino acid propeptide that is subsequently cleaved into 
smaller peptides by prohormone convertase enzymes. These include ACTH1-39 (138 to 
176 amino acid segment of POMC) as well as other POMC-derived peptides. Dopamine 
released by hypothalamic neurons inhibits POMC production in normal horses and loss of 
this regulatory control leads to increased production and release of POMC-derived 
peptides, including ACTH, in PPID-affected equids. Consequently, detection of elevated 
ACTH concentrations in peripheral blood is a commonly used test to support a diagnosis 
of PPID (van der Kolk et al. 1995; Couëtil et al. 1996; Lee et al. 2010; McGowan et al. 
2013).  
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Both pars distalis hormones and POMC-derived peptides from the pars intermedia are 
secreted into the secondary plexus of the hypothalamic hypophyseal portal system and 
subsequently flow into the cavernous sinus that lines the hypophyseal fossa of the sella 
turcica and surrounds the pituitary gland. This cavernous sinus blood contains high 
concentrations of hormones secreted by the pars distalis and pars intermedia. Fortunately, 
access to the cavernous sinus of the horse can be accomplished by insertion of a flexible 
catheter into a superficial facial vein, as first described by Irvine and Alexander (1987). 
Since that initial report, this technique has been used in numerous studies both to sample 
cavernous sinus blood to more directly assess hormone release from the pituitary gland 
(Irvine and Hunn 1984; Irvine and Alexander 1987; Alexander et al. 1996), as well as to 
measure cavernous blood temperature as an estimate of brain temperature in exercising 
horses (McConaghy et al. 1995). Using a discrete peak-detection method on ACTH 
concentrations measured in frequently collected equine cavernous sinus blood samples, 
ACTH has been found to be released in a pulsatile fashion from the pituitary gland with 
10.2 (+/- SD 1.4) ACTH concentration peaks, or pulses, per hour reported in Standardbred 
horses (Alexander et al. 1994). However, as cavernous sinus blood mixes with venous 
blood from other parts of the head while draining into the jugular vein, hormone 
concentrations decrease and pulsatility of hormone release may no longer be apparent in 
peripheral blood. Thus, measurement of ACTH in cavernous sinus blood provides a more 
direct assessment of pars distalis and pars intermedia activity, and would also provide a 
more accurate assessment of changes in ACTH concentration that may be attributable to 
treatments for PPID. 
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Anesthesia in the horse is inherently physiologically stressful which can result in 
elevations of plasma ACTH and cortisol concentrations, also known as the stress 
response (Taylor 1989). Halothane anesthesia, without attendant surgery, resulted in a 
dose-dependent stress response in horses that was attributed to cardiopulmonary 
depression (Taylor 1989; Luna 1995). Induction of general anesthesia with xylazine and 
ketamine, followed by maintenance with either halothane or isoflurane, also produced an 
increase in cortisol concentration that may have also been a consequence of 
cardiopulmonary depression (Taylor 1991). Horses maintained with isoflurane were more 
hypercapnic compared to horses anesthetized with halothane, yet horses in both groups 
were hypotensive. 
 
Over the past few decades, treatment of ACTH-dependent Cushing’s syndrome in people 
has changed from medical treatment to surgical intervention in the form of ablation of 
hypophyseal adenomas, as the current treatment of choice (Biller et al. 2008). Further, 
intra-operative ACTH measurements from both internal jugular veins provide 
information about completeness of partial-ablation and, consequently, support 
intraoperative decision making in patients with Cushing’s syndrome undergoing 
transsphenoidal surgery (Bons et al. 2014). As our research team is considering 
techniques to ablate the pars intermedia as an alternative to medical treatment of PPID 
(Sakes et al. 2015), further knowledge about factors that may affect cavernous sinus 
ACTH concentrations is needed. Specifically, pituitary gland manipulation in PPID 
horses will likely be performed under general anesthesia. Consequently, the effect of 
anesthesia on both the concentration and the pulsatility of ACTH release in both normal 
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and PPID-affected equids needs to be determined. This will allow for the assessment of 
the effects of ablation to be evaluated independent of the effects of anesthesia.  
 
The objective of the study reported here was to determine if maintenance of general 
anesthesia with isoflurane produces alterations in ACTH concentration or pulsatility in 
cavernous sinus blood. The null hypothesis stated that isoflurane anesthesia would not 
result in alterations of ACTH concentration or pulsatility in cavernous sinus blood. 
 
5.3 MATERIALS AND METHODS 
 
Six horses (5 mares and 1 gelding; 4 Quarter horses, 1 Thoroughbred and 1 Arabian) with 
mean bodyweight of 470 kg (+/- SD 32; range 427 to 500 kg) were maintained in box 
stalls and fed hay and water ad-libitum. Mean age of horses at the time of the study was 
12.2 years (+/- SD 6.0, range 7.0 to 25.0 years). Daylight length was 13.9 hours (+/- 3.1, 
range 9.4 to 16.8 hours). All animal manipulations were approved by the University of 
Saskatchewan’s Animal Research Ethics Board and adhered to the Canadian Council on 
Animal Care guidelines for humane animal use. 
 
On the day of catheter placement (Day 0), horses were sedated using a combination of 
detomidine hydrochloridea [3 mg intravenously (IV)] and butorphanol tartrateb [3 mg IV] 
administered via the jugular vein. The horses remained free-standing (restrained with a 
head halter and lead rope but not placed in stocks) during the subsequent procedures, to 
reduce the stress associated with the procedure and any subsequent effect on endogenous 
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ACTH concentration. The jugular furrows were clipped of hair and aseptically prepared. 
Hair immediately rostral to the masseter muscle mass on the left side of the face was 
clipped and similarly prepared. The facial vein was palpated in this region and 12 mL of 
2% mepivicainec was infiltrated into the dermal and subdermal layers of the proposed 6 
cm incision site using a 20 gauge (G) needle. The technique of Irvine and Alexander 
(1987) was followed. Briefly, a vertical skin incision was made through the skin 
overlying the facial vein. The sub-cutaneous tissues were carefully dissected to expose the 
vein, artery and parotid salivary duct. The vein was isolated and elevated using a loop of 
2/0 polydiaxononed suture. A #11 scalpel blade was used to make a small puncture into 
the vessel and a 7 French (Fr) G 110 cm pulmonary artery balloone (Swan Ganz) catheter 
was introduced. The catheter was advanced 30 cm through the vein into the cavernous 
sinus and then the pre-placed suture was used to fix the catheter within the vessel, thereby 
occluding it. The vein was then allowed to retract into the incision which was sutured 
closed in 2 layers (sub-cutaneous layer and skin). The remaining length of the catheter 
was secured on the head using cyanoacrylate glue and the head was bandaged to protect 
the incision and catheter. The correct position of the catheter was determined using 
radiographic confirmation initially and subsequently using a characteristic behavioral 
response that included widening eyes and cessation of chewing activity and a slight 
backward movement away from the horse handler, while the catheter was flushed with 
heparinized saline. This response did not diminish over the entire study period. The 
catheter was flushed every 8 hours to maintain patency using 3 mL of heparinized saline.  
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The following morning (Day 1) horses were restrained in box stalls using a head halter 
and lead rope. Feed was placed at head-height to encourage the horse to remain still. A 3-
way stopcock was placed onto the external end of the Swan-Ganz catheter, which was 
retracted to approximately 25 cm, and 12 mL of blood was obtained every 5 minutes for 1 
hour. The same volume of blood was concurrently removed from the ipsilateral jugular 
vein by venipuncture at 0, 30, and 60 minutes. As a result 13 cavernous sinus samples 
and 3 jugular blood samples were collected from each horse. Blood was placed into 
plastic tubes containing EDTA, stored on ice during the collection period and then 
centrifuged at 4000 rpm for 15 minutes at 4 °C. Plasma was decanted into Eppendorf 
tubes and frozen at -80 °C, within 2 hours of collection. 
 
On the day of general anesthesia (Day 2), a 14G 133 mm over-the-needle catheterf was 
placed in the left jugular vein for administration of lactated Ringers solution (10 
mL/kg/hour) and drugs. Horses were sedated with xylazine hydrochlorideg [1mg/kg IV] 
and anesthesia was induced with ketamineh [2 mg/kg IV] mixed with propofoli [0.4 
mg/kg IV]. The trachea was intubated using a 26 mm internal diameter cuffed 
endotracheal tube and the horse hoisted onto a padded operating table and placed in 
dorsal recumbency. The endotracheal tube was attached to a large animal circle breathing 
system and the lungs ventilatedj with oxygen using 10 mL/kg as the tidal volume and the 
respiratory rate adjusted to achieve an end-tidal carbon dioxide (PE’CO2) of 45 +/- 5 
mmHg (Wilson et al. 2006). Anesthesia was maintained with isofluranek in oxygen using 
a precision vaporizer. Butorphanol tartrateb was administered [0.05 mg/kg IV] as soon as 
the horse was positioned on the operating table and infused at a rate of 0.01 mg/kg/hour 
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throughout the procedure using a computerized syringe pump. Dobutaminel was used to 
maintain mean arterial blood pressure above 70 mmHg in all horses. 
A side-stream gas analyzerm measured end-tidal carbon dioxide (PE’CO2) and end-tidal 
isoflurane (PE’Iso) from a sampling port positioned in the ‘Y’ connector of the breathing 
circuit. The gas analyzer also displayed oxygen saturation of hemoglobin using a pulse 
oximeter probe placed on the tongue. A 20 SWG 48 mm over-the-needle cathetern was 
percutaneously placed into a facial artery for measurement of systemic arterial blood 
pressures using a transducero positioned at the level of the shoulder (zero-point). The 
pressure waveform was transduced through saline-filled, non-compliant tubing and 
displayed using a physiological monitorp. The physiological monitor calculated the heart 
rate from the arterial pressure waveform, and also displayed the electrocardiogram. 
Nasopharyngeal temperature was also measured in 4 horses using the same monitor. 
 
One hour after inhalant anesthesia started, at approximately the same time of day as Day 
1, the blood sampling protocol described above was repeated. At the end of the 
procedure, horses were euthanized using an overdose of sodium pentobarbitalq. The brain 
and pituitary gland were removed after euthanasia and no gross abnormalities 
(enlargement) of the pituitary gland were found. There were blood clots present within 
the cavernous sinus, with no apparent difference between the side containing the catheter 
and the non-catheterized side.  
 
Plasma ACTH concentrations were measured using a commercial sandwich assayr. The 
samples and controls (bi-level ACTH control module)s, were thawed and maintained on 
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ice until analysis.  Analyses were performed over 2 days.  Intra- and inter-assay 
coefficients of variation were 1.7% to 2.3% (n = 5) and 2.3% to 2.9% (n = 8) for control 
sera with mean ACTH concentrations of 30.4 or 400.0 pg/mL, respectively. The 
manufacturer’s stated analytical sensitivity was 9 pg/mL. 
 
Data pertaining to the horse (age, sex, breed, date of the procedure and daylight length, 
standing or anesthetized and site and time of blood collection as well as plasma ACTH 
concentration) were recorded on a spreadsheet programt and subsequently transferred to 
Windows based statistical programs.u,v  
 
Plasma ACTH concentrations were log-transformed to establish normality and 
generalized estimating equations assuming a normal distribution, controlling for repeated 
observations on individual horses were used to examine the effects of age, breed, sex, 
blood sample site (jugular vein or cavernous sinus), daylight length, time of blood sample 
and standing versus general anesthesia as variables on log-transformed plasma ACTH 
concentrations. All potential variables were initially screened using univariable analysis 
and variables for which the p-value was < 0.2 were submitted for consideration in 
building the final multivariate model (Dohoo et al. 2012). All final models were built 
using manual backwards elimination. Variables that were not significant were assessed as 
potential confounders. Where 2 or more variables were significant, biologically plausible 
2-way interactions were assessed with significant interactions retained in the final model 
(p < 0.05). Model residuals were examined to detect outliers and influential observations. 
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Furthermore, ACTH concentration time series, i.e., the collection of all cavernous sinus 
blood samples for each horse at each time-point, before and during isoflurane anesthesia 
were analyzed by means of an expressly automated deconvolution algorithm. A 
convolution integral was employed to “deconvolve” or to separate out the processes 
which give rise to the overall temporal behavior of the hormone in the data. These 
components consist of the rate of hormone entry into the bloodstream and the rate of 
hormone removal from the bloodstream. Automated deconvolution is characterized as a 
multi-parametric deconvolution-based hormone pulse identification method and considers 
4 order specific numbers: namely hormone concentration, an estimate of the precision of 
the hormone concentration, the time value, and the number of sample replicates. 
Automated deconvolution is superior to the discrete peak-detection methods in locating 
hormone secretion events as it provides crucial information about basal secretion, 
secretion-event pulse mass (pulse secretion), and elimination half-lives (Johnson et al. 
2004)w. Parameters generated via deconvolution analysis were statistically evaluated by 
means of the paired t-test, after normality was checked using with the Kolmogorov-
Smirnov test. 
 
5.4 RESULTS 
 
Physiologic data obtained from the horses during general anesthesia are presented in 
Table 5.1. There was no effect of age or daylight length on overall plasma concentration 
of ACTH, controlling for site of collection (p = 0.21 and 0.78, respectively).
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Table 5.1 Summary of specific physiological data collected for 6 horses during general anesthesia. (Data presented are mean +/- SD)  
Variable 
Time from Induction of Anesthesia (minutes) 
30 40 50 
 
60* 
 
70 80 90 100 110 120 
Mean Arterial Blood 
Pressure (mmHg) 
64 ± 14 72 ± 10 71 ± 6 72 ± 17 70 ± 13 71 ± 6 74 ± 8 67 ± 8 71 ± 9 69 ± 7 
Heart Rate (Beats per 
minute) 
37 ± 7 34 ± 5 33 ± 5 33 ± 2 34 ± 3 34 ± 4 36 ± 8 37 ± 8 37 ± 9 38 ± 12 
End Tidal CO2 
(mmHg) 
48 ± 5 46 ± 3 46 ± 3 44 ± 3 44 ± 3 43 ± 2 43 ± 3 43 ± 2 44 ± 2 44 ± 2 
Nasopharyngeal 
Temperature (o C) 
36.3 ± 0.3 36.3 ± 0.4 36.2 ± 0.5 36.1 ± 0.5 36.0 ± 0.6 36.0 ± 0.5 35.8 ± 0.4 35.8 ± 0.5 35.7 ± 0.5 35.7 ± 0.5 
Hemoglobin Oxygen 
Saturation (%) 
96 ± 3 96 ± 3 97 ± 3 97 ± 2 96 ± 4 96 ± 4 96 ± 3 95 ± 3 96 ± 3 96 ± 3 
End Tidal Isoflurane 
Concentration (%) 
1.5 ± 0.2 1.5 ± 0.2 1.5 ± 0.2 1.5 ± 0.3 1.6 ± 0.3 1.6 ± 0.2 1.6 ± 0.2 1.6 ± 0.2 1.6 ± 0.2 1.6 ± 0.2 
 
* Start of Blood Sampling
1
5
0
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Plasma ACTH concentration was significantly higher in cavernous sinus blood (499 
pg/mL +/- 190) than in peripheral blood (49 pg/mL +/- 28, p < 0.001, Table 5.2).  
 
Discrete peak detection revealed reduced average ACTH concentration per time series 
(from 549 +/- 888 to 439 +/- 668 pg/mL; p = 0.044) and the area under the concentration 
curve (from 35.2 +/- 58.0 to 28.5 +/- 43.4 ng/mL/hour; p = 0.046) during isoflurane 
anesthesia. Discrete peak detection detected 1 concentration peak per time series, whereas 
automated deconvolution analysis detected 4 secretion peaks in total, namely in 3 
standing horses (Table 5.3; ACTH half-life of 12.0, 9.2, and 2.4 minutes) and 1 out of 6 
horses during isoflurane anesthesia (ACTH half-life of only 0.3 minutes). 
 
5.5 DISCUSSION 
 
The effect of anesthesia on the physiological stress response has been classically 
measured using peripheral plasma hormone concentrations, yet the effect on pulsatility 
has not been evaluated. Our results indicate that isoflurane anesthesia leads to a reduction 
in mean ACTH concentration in the cavernous sinus of the horse and a decrease in the 
area under the curve (AUC). These results may be a function of an anesthesia induced 
reduction in the half-life of ACTH, but further work is necessary to definitively determine 
this. The reduction in mean ACTH concentration under anesthesia is different from 
earlier studies. Some, using halothane or a similar anesthetic protocol to the one we used, 
showed either an increase in ACTH concentration (Taylor 1989, 1991; Luna and Taylor 
1995), whereas others using isoflurane-anesthetized horses (Dzikiti et al. 2003), showed 
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Table 5.2 Mean plasma ACTH concentrations (pg/mL) at varying time points (minutes) 
illustrating differences between standing position (S) and general anesthesia (A), and 
between peripheral (P) and cavernous sinus (C) blood. NP* = Not Performed 
 
Time 
(minutes) 
Position 
Standing (S) 
General Anesthesia (A) 
Cavernous Sinus (C) 
or Peripheral(P) blood 
Mean 
concentration 
(pg/mL) 
Standard 
Deviation 
0 
 
S 
C 276.2 322.9 
P 17.5 9.7 
A 
C 393.4 585.1 
P 90.6 189.8 
5 
 
S 
C 136.2 172.6 
P NP* NP 
A 
C 1247.3 2350.6 
P NP NP 
10 
 
S 
C 308.6 298.5 
P NP NP 
A 
C 257.1 384.4 
P NP NP 
15 
 
S 
C 508.0 440.6 
P NP NP 
A 
C 363.7 585.2 
P NP NP 
20 
 
S 
C 599.2 733.4 
P NP NP 
A 
C 549.2 1089.1 
P NP NP 
25 
 
S 
C 1068.7 2164.5 
P NP NP 
A 
C 500.23 1021.8 
P NP NP 
30 
 
S 
C 1355.5 3001.4 
P 25.3 25.1 
A 
C 572.5 1176.2 
P 69.7 69.8 
35 
 
S 
C 538.2 1019.8 
P NP NP 
A 
C 862.4 1934.7 
P NP NP 
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Table 5.2 (cont.) Mean plasma ACTH concentrations (pg/mL) at varying time points 
(minutes) illustrating differences between standing position (S) and general anesthesia 
(A), and between peripheral (P) and cavernous sinus (C) blood. NP* = Not Performed 
 
Time 
(minutes) 
Position 
Standing (S) 
General Anesthesia (A) 
Cavernous Sinus (C) 
or Peripheral(P) blood 
Mean 
concentration 
(pg/mL) 
Standard 
Deviation 
40 
 
S 
C 240.0 327.9 
P NP NP 
A 
C 360.7 710.6 
P NP NP 
45 
 
S 
C 341.1 420.9 
P NP NP 
A 
C 307.4 411.1 
P NP NP 
50 
 
S 
C 230.3 235.0 
P NP NP 
A 
C 129.9 169.8 
P NP NP 
55 
 
S 
C 268.6 483.2 
P NP NP 
A 
C 82.4 70.3 
P NP NP 
60 
 
S 
C 1446.0 2993.8 
P 35.6 40.9 
A 
C 92.2 53.9 
P 53.9 38.3 
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Table 5.3 Outcome of deconvolution analysis, standing and under isoflurane anesthesia.  
Mean +/- standard deviation. NS = Not significant 
 
Parameter Standing Anesthesia p-value 
Mean ACTH Concentration (pg/mL) 549 +/- 888 439 +/- 668 0.044 
Area Under the Curve (ng/mL/hour) 35.2 +/- 58.0 28.5 +/- 43.4 0.046 
Number of secretion peaks 3 1 NS 
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no change in ACTH concentration.  General anesthesia typically results in hypercapnia, 
hypoxemia, hypotension, and hypothermia. These physiologic alterations can cause an 
increase in sympathetic nervous system tone and stimulate a stress response. 
 
In horses, a combination of more than 1 of these physiologic alterations may be necessary 
to increase stress hormone concentrations to a significant level (Taylor 1998). A previous 
study using pentobarbital in horses indicated preservation of arterial blood pressure may 
have decreased the physiological stress response compared to using halothane (Taylor 
1990). In our study, arterial blood pressure was maintained using intravenous fluids and 
dobutamine and use of such treatment has been found to reduce cortisol release (Taylor 
1998), which is a marker of physiological stress. However, simply maintaining arterial 
blood pressure with either dobutamine or methoxamine alone does not appear to 
completely remove the physiological stress response (Taylor 1998; Brodbelt 1998). The 
lungs of the horses in the current study were ventilated using a capnogram to guide 
ventilator settings. The capnogram can underestimate the true arterial carbon dioxide 
tension and, therefore, these horses may be considered mildly hypercapnic. Mild and 
severe hypercapnia alone, however, has not been found to increase cortisol concentration 
(Taylor 1990, 1998b; Khanna et al. 1995). In our horses, the pulse oximeter 
measurements were between 90% and 98%, but not less than 90%. The pulse oximeter 
has been found to underestimate the true hemoglobin oxygen saturation in horses, 
therefore, hypoxemia was unlikely (Koenig et al. 2003). However, arterial blood gas 
analysis was not performed to confirm the data obtained from the capnogram and pulse 
oximeter. The body temperature as measured in the nasopharyngeal area decreased over 
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time and hypothermia may initiate a physiological stress response, but mild hypothermia 
has been found to decrease the concentration of stress hormones (ACTH and cortisol) in 
humans (Oak et al. 2001). 
 
Induction of anesthesia with xylazine and ketamine has not been found to increase serum 
cortisol in horses (Robertson 1987).  Cortisol concentration did not increase until 60 and 
80 minutes following xylazine administration in halothane and isoflurane anesthetized 
ponies, respectively (Taylor 1991). Alpha-2 adrenergic agonists are known to suppress 
the stress response, as determined by measuring plasma ACTH concentrations, by 
decreasing sympathetic tone (Taylor 1991; Alexander and Irvine 2000) and, therefore, the 
decision to begin collecting blood samples 60 minutes after induction was made to 
ameliorate the significant hypophyseal suppression occurring with xylazine given for 
premedication. However, the effect of xylazine alone on cortisol or ACTH concentration 
in the horses has not been well studied. Detomidine has been found to decrease or not 
change cortisol concentration in horses, and medetomidine or xylazine did not change 
cortisol concentration in dogs (Raekallio et al. 1992; Carroll et al. 1997; Ambrisko and 
Hikasa 2002). Butorphanol was used in this study as part of a concurrent study examining 
histamine release from use of opioids. Butorphanol infusions, however, have not been 
found to influence serum cortisol concentrations in horses under anesthesia (Dias et al. 
2014). Propofol was used as a co-induction agent with ketamine and was unlikely to 
influence the results 60 minutes following the low dose used, although this has not been 
confirmed in horses (Ruane-O’Hora et al. 2011).  
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Cavernous sinus blood had significantly higher concentrations of plasma ACTH 
compared to jugular vein blood which can be explained by a dilutional effect of venous 
blood draining from other areas of the head and neck. The gradient in ACTH 
concentration between cavernous sinus and jugular plasma can be over 33 to 50-fold in the 
equine species (Luna and Taylor 1998), compared to the 10 to 20-fold (depending on the 
time-point) in the current study. When our results were compared to more commonly used 
discrete peak-detection methods, not only was the amount of ACTH secreted over the 
sampling period significantly reduced during anesthesia, but the number of concentration 
peaks were also minimal prior to and during anesthesia. No doubt the latter was due to 
differences in assay characteristics, specifically a rather high hormone detection limit of 9 
pg/mL and a single replicate (measurement) used in this case. Furthermore, only a single 
secretion peak was noted under anesthesia, compared to only 3 secretion peaks detected 
in the unsedated standing horse. These differences are also likely due to the assay 
characteristics used by the automated deconvolution methodology.   
 
The use of interventional radiological techniques for the intravascular treatment of a 
variety of neoplasms, developmental and acquired abnormalities is increasing in humans 
and small animals.  In order to be confident of a treatment effect, other possible 
confounding factors such as pathophysiological effects of anesthesia and anesthetic drugs 
must be considered. The current study indicates that if manipulation of the pituitary gland 
in-situ is successful for the treatment of PPID, simple measurement of plasma ACTH 
concentration, especially if minimal, in cavernous sinus blood may not be a reliable 
indicator of interventional success which would have to be interpreted in light of effects 
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of general anesthesia.  Further work is necessary to determine appropriate methods of 
assessing immediate effects of interventional therapies applied to the pituitary gland. 
 
Footnotes: 
a Dormosedan, Pfizer Animal Health, Pfizer Canada Inc., Kirkland, QC, Canada 
b Torbugesic, Ayerst Laboratories, Pierrefonds, QC, Canada 
c Carbocaine, Pfizer Animal Health, Pfizer Canada Inc., Kirkland, QC, Canada 
d PDS II, Ethicon US LLC, Cincinati, OH, USA 
eSwan-Ganz, Edwards Lifesciences LLC, Irvine, CA, USA 
f BD Angiocath, Becton Dickinson, Infusion Therapy Systems Inc., Sandy, UT, USA 
g Rompun, Bayer Healthcare, city, ON, Canada) 
h Vetalar; Bioniche Animal Health, Belleville  ON, Canada 
i Propoflo; Abbott Laboratories, Saint-Laurent, QC, Canada 
j Dräger AV, Anesthesia Ventilator, North American Dräger, Telford, PA, USA 
k Isoflo, Abbott Laboratories, Saint-Laurent, QC, Canada) 
l Dobutamine injection USP, Sandoz Canada Inc. Boucherville, QC, Canada 
m POET IQ Anesthesia Gas Monitor, Criticare Systems Inc., WI, USA 
n BD Insyte, Becton Dickinson, Infusion Therapy Systems Inc., Sandy, UT, USA  
o Truwave Disposable Pressure Transducer, Edwards Lifesciences LLC, Irvine, CA, USA 
p PB240 Operating Room Monitor, Puritan Bennet Corporation, city, MA, USA 
q Euthanyl Forte, Bimeda-MTC Animal Health Inc., Cambridge, ON, Canada. 
r Siemens ACTH kit and Immulite 1000 Chemiluminescent System, Siemens Canada, 
Oakville, ON, Canada 
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s bi-level ACTH control module, Siemens Canada Oakville, ON, Canada 
t Microsoft Excel, Microsoft Canada Inc, Mississauga, ON, Canada 
u  SPSS, IBM Canada Ltd, Markham, ON, Canada 
v PULSE XP, Pulse Analysis Software, University of Virginia, Charlottesville, VA, USA. 
w https://www.researchgate.net/publication/262566415_AutoDecon_and_Pulse_XP_Software. 
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CHAPTER 6 
 
DEVELOPMENT OF A NOVEL SURGICAL APPROACH TO 
THE TREATMENT OF PITUITARY PARS INTERMEDIA DYSFUNCTION 
IN THE HORSE 
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CHAPTER 6 
TRANSITION PAGE 
Development of a novel surgical approach to the treatment of pituitary pars 
intermedia dysfunction in the horse. 
This chapter presents the progression through various surgical approaches to the 
treatment of PPID in the horse and settles on a minimally invasive trans-venous 
fluoroscopic guided injection of the pituitary gland. The benefits and drawbacks of each 
method is explained and an in-depth assessment of the benefits of the minimally invasive 
method is given. 
This work is important because it forms the basis for the next step in this line of 
investigation. The surgical manipulation of the gland in PPID horses will bring about a 
single intervention leading to palliation, or permanent cure of the condition in the 
affected horse. 
Copyright statement:  This Chapter has been submitted for publication. The copyright 
of this Chapter will belong to the journal in which it is published. 
Full citation: Carmalt JL and Scansen BA. Development of a novel minimally invasive 
surgical approach to the treatment of PPID in the horse. Veterinary Surgery 2017. 
Submitted. 
Author contributions: Carmalt conceptualized and tested the myeloscopic approach (a 
modification of a previously published technique). Carmalt (together with graduate and 
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summer students) conceptualized, designed and tested the trans-sphenopalatine sinus and 
the trans-basisphenoidal osteotomy approaches. Carmalt modified a previously published 
minimally invasive blood collection technique to approach the pituitary gland for 
treatment purposes and Scansen provided expertise in fluoroscopic guidance and 
interventional radiological techniques. Carmalt wrote the manuscript with Scansen 
providing editorial assistance.  
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6.1 ABSTRACT 
 
Objective: To develop a safe, repeatable surgical modality for the treatment of pituitary 
pars intermedia dysfunction (PPID) in the horse. 
Materials and Methods: Four surgical approaches to the pituitary gland were 
investigated: a myleoscopic technique via the foramen magnum, a trans-sphenopalatine 
sinus technique via maxillary sinusotomies, a ventral trans-basispheniodal osteotomy and 
a minimally invasive intravenous approach via the ventral cavernous sinus. 
Results: Significant bleeding and a failure to obtain the correct angle of approach 
prevented the myeloscopic and trans-sphenopalatine sinus techniques from being 
successful. The ventral basisphenoidal osteotomy was repeatable and has potential if an 
intra-operative imaging guidance system could be employed. The minimally invasive 
approach was repeatable, atraumatic and relatively inexpensive.   
Conclusions: Current treatment of PPID typically requires daily oral medication, which 
is expensive and difficult from a management perspective. A minimally invasive surgical 
palliation of this chronic condition is appealing because it is envisioned to be a single 
treatment which, while not curative, will return the horse to a symptom-free state and 
dramatically improve the welfare of the horse. More work is necessary to determine what 
that treatment might be, but for the current time, access to the pituitary gland has been 
obtained, which is a promising step.  
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6.2 INTRODUCTION 
 
Pituitary pars intermedia dysfunction (PPID) or equine Cushing’s disease is a common 
endocrine disease of the older horse. Dopamine released by hypothalamic neurons 
inhibits proopiomelanocortin (POMC) production in the pars intermedia of normal 
horses. A loss of this control leads to hypertrophy and hyperplasia of pars intermedia 
melanotrophs with concomitant increases in the production of POMC (Millington et al. 
1998; McFarlane 2011). This 241 amino acid propeptide is subsequently cleaved into 
smaller peptides by prohormone convertase enzymes. These include adrenocorticotrophic 
hormone (ACTH1-39; 138-176 amino acid segment of POMC) as well as other POMC-
derived peptides.  
 
PPID horses with hypertrophy and hyperplasia of the pars intermedia have a grossly 
enlarged pituitary gland (van der Kolk et al. 2004; McFarlane et al. 2011; Leitenbacher 
and Herbach 2016). The relative positioning of this region of the gland, which is 
sandwiched between the pars distalis and the pars nervosa, makes selective pars 
intermedia ablation complicated. Complete ablation of the pituitary gland would result in 
a multitude of other hormonal imbalances which would require daily medication, which 
is no better than the current standard of care treatment regime involving daily oral 
pergolide, a dopamine receptor agonist.  
 
The preferred method of treating ACTH-dependent hyperadrenocorticism in people and 
dogs is the surgical ablation of hypophyseal adenomata (Biller et al. 2008; Meij et al. 
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1998; Mamelak et al. 2014). Brain surgery is rarely performed in the horse. There are 
single case reports of the drainage of brain abscesses after localization using computed 
tomography (CT) (Allen et al. 1987; Cornelisse et al. 2001; Janicek et al. 2006), and a 
CT-guided biopsy of an intra-cerebral mass, which was subsequently diagnosed as a 
cholesterinic granuloma (Vanschandevijl et al. 2008). Kramer et al. (2007) reported on 3 
approaches to the equine cranium (rostrotentorial, suboccipital and the transfrontal) in 
cadaver heads, which gave limited access to the rostral, dorsal and caudal aspects of the 
cerebral cortex and cerebellum. No described approach gave access to the hypophysis. 
There is a single case report of an open craniotomy and severing of the hypothalamic-
pituitary axis using a laser (Locatelli 1984), which unfortunately does not describe the 
technique or outcome sufficiently well to allow repetition. 
 
Other possible options for hypophyseal access include myeloscopy which has been 
described for visualization of the floor of the vertebral canal in cases of cervical vertebral 
malformation (Prange et al. 2011a, 2011b, 2012); a trans-sphenopalatine sinus approach 
modelled on the human techniques; a ventral trans-basispheniodal osteotomy; and a 
transcatheter approach utilizing access to the cavernous sinus of the horse originally 
published as a technique for pituitary effluent blood sampling (Irvine and Hunn 1984; 
Irvine and Alexander 1987; Alexander et al. 1994, 1996; Bons et al. 2014; Sakes et al. 
2015). 
 
The hypothesis of this study was that a surgical approach to the equine pituitary gland is 
feasible allowing for the further development of methods to ablate the pars intermedia. 
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The objective of the study was to develop a novel surgical technique for access to the 
pituitary gland in the horse. 
 
6.3 MATERIALS AND METHODS 
All of the procedures documented below were performed on cadaver heads, or in 
complete horse carcasses (unless otherwise expressly stated) during the development 
phase. Two of the procedures were subsequently performed in the live horse under a 
terminal general anesthesia protocol. All animals and cadaveric parts were used under 
approval of the Institutional Animal Use and Care Committee of the institution in which 
the work was performed. 
 
6.3.1 MYELOSCOPIC APPROACH 
Two entire cadavers were used for the development of this technique. A variation of the 
previously published cervical myeloscopy technique was used but altered such that the 
endoscope was directed cranially, rather than caudally (Prange et al. 2011a,b, 2012). 
 
Briefly, the cadavers were placed in right lateral recumbency with the head flexed by 
tying the head collar to the proximal forelimbs. A dorsal midline incision was made 
centered on the cranial edge of the atlas and the underlying musculature separated. The 
epidural space was entered and the slim endoscopea advanced abaxially and cranially 
under the spinal cord to enter the cranium through the foramen magnum. In each horse, 
significant hemorrhage was encountered during the approach. Despite repeated flushing 
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of the endoscope portal using lactated Ringers’ solution, visualization was impaired to the 
point that the procedure was terminated. 
 
6.3.2 TRANS-SPHENOPALATINE SINUS APPROACH 
Five cadaveric heads, collected immediately postmortem and frozen until use at -20 °C 
were used. Heads were thawed in warm water for 24 hours and subsequently drained of 
water before use. Heads were positioned with the mandibles on a non-slip table to mimic 
sternal recumbency under general anesthesia. 
 
A 2 cm incision was made parallel to the long axis of the head, 4 cm rostral to the 
palpable limit of the medial canthus of the eye and 4 cm lateral to the midline of the head 
on the left side. The skin was separated using hemostats and the underlying bone 
exposed. The rostral region of the dorsal conchal sinus was entered using a 9 mm Galt 
trephine. A 6 mm outer diameter flexible endoscope with a working biopsy channela was 
used to explore the caudal maxillary sinus system and the entrance to the sphenopalatine 
sinus. Under visual endoscopic guidance, a caudally facing obliquely angled hole was 
then made using the same technique immediately under the bony portion of the 
nasolacrimal duct half the distance between the medial canthus of the eye and the 
palpable border of the infraorbital foramen. A 2 mm orthopedic drill bit was introduced 
into the second hole and visually directed into the opening of the sphenopalatine sinus. 
Unfortunately this placed the tip of the bit too rostral and the working osteotomy was 
subsequently moved further rostral, entering the rostral maxillary sinus. The ventral 
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conchal bulla then had to be removed using biopsy forceps through the flexible 
endoscope so that the drill tip could pass through the caudal maxillary sinus and enter the 
ostium of the sphenopalatine sinus. Despite this modification, the caudal extent of the 
sphenopalatine sinus could not be accessed on the ipselateral side and as such the 
technique was abandoned. 
 
6.3.3 VENTRAL TRANS-BASISPHENIODAL OSTEOTOMY APPROACH 
 
Five cadaveric heads, collected immediately postmortem and frozen until use at -20 °C 
were used. Heads were thawed in warm water for 24 hours and subsequently drained of 
water before use. Heads were positioned to mimic dorsal recumbency under general 
anesthesia and the nose was tipped up to ensure that the base of the skull was parallel to 
the surgery table.  
 
A flexible endoscopea was advanced via the right external nares and the ventral nasal 
meatus into the nasopharynx. A 25W diode laser fiberb was passed via the biopsy portal 
and the tissue of the dorsal pharyngeal recess was ablated using contact mode, as 
previously published for the treatment of guttural pouch tympany in foal (Edwards and 
Greet 2007). This allowed simultaneous entry into both guttural pouches and resection of 
the membrane separating the left and right pouches. A standard laryngotomy approach 
was made (Fulton et al. 2012) by creating a 10 cm incision on the ventral midline starting 
immediately caudal to the palpable margin of the thyroid cartilage and proceeding 
caudally to the cricoid cartilage. The sternothyrohyoideus muscles were separated through 
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their aponeuroses and retracted using Weitlaner retractors. The loose adventitial tissue 
overlying the cricothyroid membrane was separated, taking care to ligate the small vessel 
usually present in this location. The cricothyroid membrane and the mucosa of the airway 
on the dorsal aspect were sharply transected with a #10 scalpel blade. A long, 12 mm 
wide standard laparoscopic trochar and cannulac was then advanced into the laryngotomy. 
The trochar was slightly withdrawn to allow the smooth edge of the cannula to sit 
between the corniculate processes of the arytenoid cartilages. By angling the cannula 
slightly rostrally while engaging the position and then moving it to a vertical position the 
entire larynx was displaced caudally. The sharp trochar was re-introduced and using 
verbal guidance from an assistant sighting midline of the horse and another checking the 
verticality of the cannula, in addition to using visual guidance from the flexible 
endoscope placed within the guttural pouch, the cannula was thrust through the roof of 
the nasopharynx. It was advanced until the tip of the trochar engaged the basisphenoid 
bone immediately rostral to the insertion of the paired longus capitis and longus capitis 
ventralis muscles within the guttural pouch. The trochar was removed and an auger drill 
bit, which had a guiding thread on the distal extent, was fed into the cannula to protect the 
surrounding soft tissues. A slot osteotomy was drilled through the basisphenoid bone 
under visual and digital radiographic guidance and then laparoscopic forceps were used to 
remove the final pieces of bone and confirm entry into the cranium. In this position, the 
pituitary gland was visible immediately under the bone, fixed to the floor of the sella 
turcica, and the ventral cavernous sinuses were abaxial to the drill hole (Figure 6.1).  
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Figure 6.1 A photograph of the brain and caudal nasal passages of an equine cadaver 
head. Rostral is to the right and caudal to the left. 
 
 
 
 
 
 
 
 
 
 
 
Legend: The blue arrow denotes the hypothalamus, the red circle denotes the optic chiasm 
and the blue star illustrates the position of the sphenopalatine sinus. The oblique metal 
rod indicates the position of the pituitary gland while the vertical rod indicates a trans-
basisphenoid approach to the gland which has been positioned too far caudally.  
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Following cadaveric success, the procedure was performed in a single, live horse under a 
terminal anesthetic protocol. 
 
6.3.4 INTRAVENOUS (MINIMALLY INVASIVE) APPROACH 
Three cadaveric heads, collected immediately postmortem and frozen until use at -20 °C 
were used. Heads were thawed in warm water for 24 hours and subsequently drained of 
water before use. Heads were positioned to mimic right lateral recumbency under general 
anesthesia and the nose was tipped up to ensure that midline of the skull was parallel to 
the fluoroscopy systemd. 
 
The technique of Irvine and Alexander (1987) was followed. Briefly, the hair 
immediately rostral to the right masseter muscle mass on the lateral aspect of the face was 
clipped and aseptically prepared to remove surface debris and hair particles. A vertical 
skin incision was made through the skin overlying the deep facial vein. The sub-
cutaneous tissues were carefully dissected to expose the deep facial vein, the facial artery 
and parotid salivary duct. The vein was isolated and elevated using a loop of 2/0 
polydiaxonone suture. A #11 scalpel blade was used to make a small puncture into the 
vein and a 7 French (Fr)  gauge (G) 110 cm pulmonary artery balloon catheter (Swan-
Ganz)e was introduced (Figure 6.2 and 6.3A, B). The catheter was advanced 25 cm and 
correct placement within the ventral cavernous sinus (Figure 6.4) was confirmed by 
injecting 5 mL of 240 mgI/mL Iohexol contrast solutionf and visualizing the contrast 
column fluoroscopically in the lateral and ventrodorsal imaging planes.  
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Figure 6.2 A cadaver dissection showing the position of the vein, artery and parotid 
salivary duct (yellow arrow) in a mature horse. Rostral is to the left.               
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Figure 6.3A Placement of the Swan-Ganz catheter in the left deep facial vein. Rostral is 
to the left. 
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Figure 6.3B A cadaver dissection showing the catheter advanced via the right deep facial 
vein into the orbital fissure. Rostral is to the right.* 
                       
* See Chapter 1 for a description of the venous drainage of the ventral cavernous sinus.  
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Figure 6.4 A cadaver dissection, showing the placement of the 7FG Swan-Ganz catheter 
in the ventral cavernous sinus of the brain having entered via the orbital fissure.* 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: Note the position of the catheter lateral to the retained pituitary gland (*). The 
optic chiasm is noted (OC). 
* See Chapter 1 for a description of the venous drainage of the ventral cavernous sinus.  
 
OC 
* 
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Correct entry into the cavernous sinus resulted in visible contrast flow around a large, 
central filling defect, which was the pituitary gland (Figure 6.5A and B). 
 
A 0.038” diameter, 145 cm length fixed core straight guide wire was advanced within the 
Swan-Ganz catheter to the cavernous sinus under fluoroscopic guidance and the Swan-
Ganz catheter was then withdrawn. A 45 cm 8Fr G angled introducer sheath was 
advanced over the guide wire, and the tip of the sheath positioned within the cavernous 
sinus using intermittent administration of iohexol contrast solution and fluoroscopy to 
confirm location. When in the correct position, the wire guide was removed and replaced 
with a 56 cm 22Fr G trans-septal needlei. The needle was passed through the sheath and 
directed into the pituitary gland under fluoroscopic guidance. The gland was then injected 
with a combination of radiopaque contrast material and new methylene blue dye. 
Confirmation of gland injection was accepted when “tumor blush” was seen 
fluoroscopically (Figure 6.6). Instrumentation was removed and the cranium was opened. 
The brain was removed leaving the pituitary gland in-situ and new methylene blue dye 
could be visually appreciated within the glandular tissue. 
 
The same procedure was then performed in a live, clinically normal horse and a single 
aged mare with hirsutism and laminitis (consistent with PPID) under terminal anesthetic 
procedures. 
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Figure 6.5A A dorso-ventral fluoroscopic image of the cranium showing the catheter tip 
(arrows) adjacent to the pituitary gland (not visible). The caudal aspect of the pituitary 
gland is indicated by the tip of the scissors placed within the foramen magnum of the 
cadaveric head and advanced until the gland was touched. 
 
 
 
 184 
 
Figure 6.5B A dorso-ventral fluoroscopic image of the cranium showing contrast flow in 
the ventral cavernous sinus around a central filling defect which represents the pituitary 
gland. Note the presence of the catheter (black arrow), the flow of contrast material into 
the emissary veins (white arrows) and the central defect representing the pituitary gland 
(star)  
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Figure 6.6 A dorso-ventral subtraction angiographic image of the cranium showing the 
catheter (X), needle placement within the pituitary gland (white arrow), “tumor blush” 
(delineated by arrows) around the needle, and extra contrast material filling the ventral 
cavernous sinus after injection. 
 
 
 
 
 
 
X 
 186 
 
6.4 RESULTS 
 
The myeloscopic approach to the hypophysis was not successful. In each attempt 
hemorrhage prevented adequate visualization, despite flushing the endoscope with 
lactated Ringers solution, and the procedure was abandoned. It is possible that with 
further practice the technique could have been finessed, and certainly, the bleeding during 
endoscope placement has been previously reported (Prange et al. 2011b) and overcome.  
 
The trans-sphenopalatine sinus approach failed due to a lack of appropriate 
instrumentation and anatomical variations between the horse and the human, upon which 
the technique had been based. Despite a very steep angle of the drill tract (rostro-lateral to 
caudomedial), passing through the rostral and caudal maxillary sinuses into the opening 
of the sphenopalatine sinus, the drill tip was still too rostral and the back of the 
sphenopalatine sinus could not be accessed. Further, the intimate proximity of the optic 
chiasm relative to the pituitary gland would have rendered this technic unfeasible. 
 
The ventral trans-basispheniodal osteotomy was reproducible and ablation of a portion (or 
all) of the pituitary gland was possible from this position using whichever method the 
surgeon might choose. After cadaveric success, the procedure was performed in a single 
live horse under a terminal anesthetic protocol. The procedure was performed as above, 
however, an error in the drill position resulted in inadvertent entry into the ventral 
cavernous sinus and uncontrollable hemorrhage. At this point the horse was humanely 
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euthanased by intravenous injection of Pentobarbitolj into the jugular vein, without 
allowing it to recover from surgery. 
 
In the 3 cadavers and 1 live, clinically normal, horse that underwent the minimally 
invasive transcatheter approach, access to the cavernous sinus and injection into the 
pituitary gland was possible and repeatable. Cut sections of the pituitary gland after 
minimally-invasive injection of methylene blue revealed intra-pituitary staining. A single 
aged mare with clinical signs consistent with PPID was subsequently subjected to the 
same procedure. Access to the cavernous sinus was achieved without complications but at 
postmortem examination it was clear that the needle had been directed slightly too far, 
with the result that the injected methylene blue had not entered the pituitary gland, but 
had been deposited into the cavernous sinus blood immediately caudal to the gland. 
 
6.5 DISCUSSION 
 
We report 4 surgical approaches to the equine pituitary gland, with the ventral trans-
basisphenoidal osteotomy and the minimally-invasive transcatheter approaches showing 
promise for the potential treatment of equine PPID. A surgical method to access the 
equine pituitary gland may allow surgical resection or chemical ablation of abnormal pars 
intermedia tissues, thereby controlling clinical signs of PPID in affected horses and 
avoiding daily oral medications. 
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The treatment of pituitary tumors in humans is most often multimodal and encompasses, 
microsurgical, radiosurgical, radiation and medical treatments. Endonasal surgical 
approaches to the skull base (microscopic or endoscopic), and in particular the transsellar 
approach to the pituitary gland, have been well described (Joshi and Cudlip 2008; Miller 
et al. 2014). Despite the endoscopic approach gaining traction there is, as yet, no firm 
consensus on whether the microscopic or endoscopic technique is superior (Jane et al. 
2005; Kasemsiri et al. 2014; Cappabianca et al. 2014). In either case, a profound 
knowledge of the anatomical relationships in the skull base region is required (Budu et al. 
2013). 
 
The pituitary gland of the herbivorous quadrupeds lies ventral in the cranium within the 
hypophyseal fossa of the sella turcica. It is surrounded by the ventral cavernous sinus into 
which both pars distalis hormones and POMC-derived peptides from the pars intermedia 
are secreted. The comparatively long nasal passages and large paranasal sinuses of the 
horse, as well as the anatomical difference in the position of the hypophysis compared to 
humans, makes surgical access through the equine sphenopalatine sinus extremely 
difficult. As illustrated in Figure 6.1, the surgical approach is complicated by the position 
of the optic chiasm which lies directly between the caudal extent of the air-filled sinus 
and the rostral margin of the hypophysis. Even if the surgeon were to manage to position 
the osteotomy ventral to the optic chiasm, they would inevitably enter the rostral portion 
of the blood-filled ventral cavernous sinus which would result in significant hemorrhage.  
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The nasal passage issue has been overcome in the dog by utilizing an oral approach and 
computed tomographic guidance (Mamelak et al. 2014). Unfortunately, the horse mouth 
does not open wide enough to permit use of this technique and a modification (the ventral 
trans-basispheniodal osteotomy) was devised for use in the horse. It was technically 
demanding requiring competent use of the flexible endoscope, laser and neurosurgical 
skills. Accurate positioning was absolutely critical so as not to miss the hypophysis and 
enter the surrounding vascular sinus spaces. Use of a stereotactic frame as well as 
advanced image guidance such as the STEALTH neurosurgical imaging and surgical 
navigation systemk as used in human surgery would have greatly aided in technique 
development and may have improved success rates. However, it is cost prohibitive at the 
current time. Additional possible surgical complications are associated with damage to 
the vessels and nerves of the guttural pouch through which the basisphenoid bone is 
accessed. Guttural pouches are a diverticulum of the auditory tube, present in 
Perissodactyls (e.g., equine, tapir, rhinoceros) and other species (Brandt 1863; Hinchcliffe 
and Pye 1969).  In the horse, it occupies the space extending from the roof of the pharynx 
to the base of the skull and from the atlanto-occipital joint to the pharyngeal recess.  Each 
pouch has a volume of 300 to 500 mL and is divided into a medial and lateral 
compartment by its reflection of the mucosal lining around the dorsal, lateral and medial 
surfaces of the stylohyoid bone.  The pouches are so large that they are joined at their 
rostro-medial aspects, forming a medial septum.  The unique shape of the guttural pouch 
is created by myriad structures to which it is physically attached and encompasses 10 
arteries, 5 cranial nerves, 7 muscles, as well as lymph nodes, the parotid salivary gland, 
bones of the skull and mandible, and adipose tissue. 
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There are multiple reported surgical approaches to the guttural pouch. The 
hyovertebrotomy, also known as the Dorsal approach and Dieterich's Method, 
(McIlwraith and Turner 1987), access via Viborg’s triangle (McIlwraith and Turner 
1987), the Whitehouse and modified Whitehouse approaches, also known as the Ventral 
approach or the Sand’s method, (McAllister 1978; Freeman 1992) and the Garm method 
(Garm 1946). Irrespective of the chosen approach the most common surgical 
complication is intractable dysphagia, which can lead to aspiration pneumonia and death 
(Freeman 1990). Despite this, the ventral trans-laryngeal approach to the midline of the 
basisphenoid bone was considered to present the least risk because of the relatively 
atraumatic nature of the laparoscopic cannula placement and the added benefit of soft 
tissue protection during the creation of the osteotomy as the drill was contained within the 
laparoscopic cannula. 
 
Interventional radiology is defined as a “therapeutic and diagnostic specialty that 
comprises a wide range of minimally invasive image-guided therapeutic procedures as 
well as invasive diagnostic imaging” (Society of Interventional Radiology 2010). In the 
head and neck, this technique can be used (amongst others) for tumor embolization, 
occlusion of vascular malformation such as arterio-venous fistulas, treatment of 
aneurysms, radiofrequency ablation and cryoablation of tumors and venous sampling, 
specifically of hormonal output to predict successful treatment intra-and post-surgery 
(Yen et al. 2008; Broomfield et al. 2009; Jindal et al. 2012). 
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Interventional radiology is used in equine surgery for the embolization of the internal 
carotid, external maxillary or major palatine arteries in cases of guttural pouch mycosis. 
A mechanical device, such as a balloon catheter (Freeman and Donawick 1980) or 
thromboembolic coils (Matsuda et al. 1998; Lepage and Piccot-Crézollet 2005; 
Benredouane and Lepage 2012) are subsequently used to occlude the offending vessel. 
Similar treatment of a palatine artery pseudoaneurysm with right sided epistaxis has also 
been reported (McLellan et al. 2014).  
 
The internal carotid artery passes through the guttural pouch on the caudo-medial wall, 
enters a sigmoid curve and then the cranium via the foramen lacerum. It then gives rise to 
the rostroventral infundibular (hyophyseal) arteries supplying the ventral capillary 
network of the median eminence of the hypothalamus (Vitums 1975). Ventral and dorsal 
hypophyseal vessels descend through the pars tuberalis to supply blood to the distal part 
of the adenohypophysis terminating in the sinusoidal network of the pars distalis. The 
right and left caudal infundibular arteries arise from the caudal intercarotid artery and, in 
some cases, the internal carotid artery, and running in a sheath of dura mater, pass 
through the intercavernous sinus to become a capillary network in the most distal aspect 
of the pars nervosa and infundibular stalk. Passage of a guide wire and catheter beyond 
the internal carotid artery junction with the rostroventral infundibular artery has not 
proven possible in our cadaveric work due to the acute angle and tortuous nature of this 
junction (data not shown). A transarterial approach to the pituitary gland to deliver either 
coils, particles (such as polyvinyl alcohol, embospheres or gelfoam) or liquid embolics 
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(Jindal et al. 2012) into the direct arterial supply of the pars intermedia and thus spare the 
remainder of the gland from damage was initially envisioned, but could not be realized. 
 
There are two paths of venous drainage; caudoventrally into the ventral petrosal sinus and 
foramen lacerum and secondly, rostrolaterally into the ophthalmic vein and the deep 
facial vein (Vitums, 1978). This latter path was exploited for long-term sampling of 
pituitary effluent blood (Irvine et al. 1984; Irvine et al. 1987; Alexander et al. 1996). Use 
of a minimally invasive transvenous approach, as outlined above, to access the pituitary 
gland in the horse cadavers of this report was successful and repeatable. It allowed the 
passage of a long flexible needle through the introducer sheath in isolated heads and in 
the live anaesthetized horses, under fluoroscopic guidance, to access and inject dye into 
the pituitary gland. 
 
Sakes et al. (2015) published on the use of a motorized resector to partially ablate the 
gland using this transvenous access route, however, the future vision is that a neurolytic 
(such as ethylalcohol, or glycerol) or a melanotroph-specific targeting agent (Lau et al. 
2015; Kaiser 2015) could be injected under guidance and result in partial ablation of the 
pituitary gland. In advanced stages of disease the proportion of the gland that is 
represented by the pars intermedia would be much greater (Leitenbacher and Herbach 
2016) and thus the majority of damage caused would be directed at the offending portion 
of the hypophysis, however, it is likely that collateral damage to the pars nervosa or the 
pars distalis may also occur. The degree of lysis or ablation of the pars intermedia 
required to return the horse to clinical normalcy is unknown. The aim would not be to 
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completely deprive the horse of the hormone output of the pars intermedia, but merely to 
disable a sufficient amount of this specific region as to improve the quality of life of these 
aged horses. 
 
In conclusion, of all the surgical approaches developed to access the equine hypophysis, 
the transvenous approach to the ventral cavernous sinus of the cranium using 
interventional radiology is the least invasive. It is repeatable and, other than fluoroscopy, 
requires the least expensive equipment and arguably is least complicated. Further work is 
needed to determine which method of ablation is most effective, and how much can be 
ablated while preserving the critical homeostatic mechanisms of the gland. While 
hormone supplementation is simple and easy to use in human medicine after tumor 
ablation, anything other than complete resolution of clinical signs will be unsuitable in 
the horse because there is already an oral daily medication for PPID. 
 
Footnotes: 
a Olympus GIF-XP160, Olympus Corporation, Philadelphia, USA. 
b DiodeVet, Newark, Delaware, USA. 
c VersaportTM Plus, Bladeless trochar, Medtronic, Minneapolis, MN, USA   
d OEC 9900 Elite Cardiac C-Arm; GE Healthcare, Inc.; Salt Lake City, UT, USA 
e Swan Ganz, Edwards Lifesciences LLC, Irvine, CA, USA 
f Omnipaque; GE Healthcare, Inc.; Princeton, NJ, USA 
g Straight wire guide; TSF-38-145; Cook Medical, Inc.; Bloomington, IN, USA 
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h Angled introducer sheath ; KCFW-8.0-18/38-45-RB-ANL1-HC; Cook Medical, Inc.; 
Bloomington, IN, USA 
i Transseptal needle; TSNC-19-56.0 Cook Medical, Inc.; Bloomington, IN, USA 
j Pentobarbital sodium; Euthanyl Forte, Bimeda-MTC Animal Health Inc., Cambridge, 
ON, Canada. 
k StealthStation S7 Surgical Navigation System, Medtronic, Minneapolis, MN, USA 
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CHAPTER 7 
 
GENERAL DISCUSSION 
 
7.1 INTRODUCTION 
 
Equine pituitary pars intermedia dysfunction (PPID), also known as equine Cushing’s 
disease, is a common endocrine disease of older horses (Orth et al. 1982; Schott 2002). 
The condition is associated with an enlargement of the pars intermedia of the pituitary 
gland. Initially reported as a neoplasm, an adenoma, it is now known that the hyperplasia 
and hypertrophy of this selective region of the pituitary gland is due to a lack of 
dopaminergic inhibition from the hypothalamus (McFarlane 2007). The abnormal cells 
produce high levels of hormone which lead to a number of clinical signs. The most 
readily detected is hypertrichosis, which often leads the owner to seek veterinary attention 
(McFarlane 2011; Schott et al. 2017). A diagnosis is usually made by performing a 
laboratory test after clinical examination. There are several test options, however, none 
are of high enough specificity and sensitivity to be categorized as a definitive antemortem 
test. 
 
Despite advances in the understanding of the pathophysiology of PPID, the treatment, 
which was first described in the 1980s – the daily, lifelong, oral administration of 
pergolide mesylate, a dopamine receptor agonist – is still the most widely used therapy 
that the veterinary profession has to offer. The caveat in the development of a new 
treatment is that it must be as least as good as, if not better than, the current treatment. 
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This means that the dosing interval must be less frequent than every day, and ideally, a 
single application. Theoretically, pituitary ablation in-toto, as occurs for treatment of this 
condition in the dog (Meij 1997), or in part, as occurs in cases of human pituitary 
enlargement (Krisht 2002; Cappabianca 2004) may be a useful treatment option. Given 
the myriad hormones produced by the pituitary gland, most of which appear unaffected by 
PPID, in-toto removal is questionable in the horse, leaving researchers to develop a 
selective ablative procedure.  
 
7.2 GENERAL RESULTS AND FUTURE STUDIES 
 
The long term goal of this research was to explore the feasibility of developing a targeted 
tissue-specific approach for the treatment of equine PPID. This thesis constitutes a first 
approach to this goal.  
 
The first specific aim, to confirm the need for this advanced therapy by determining the 
prevalence of PPID in horses globally, was achieved using an international online survey 
of over 400 veterinarians in 20 countries (Chapter 2). It showed that 84% of respondents 
had at least 1 horse with PPID under their care, with half of the veterinarians reporting at 
least 5 horses with PPID. The estimated prevalence of PPID was approximately 1%, 
which is consistent with other reports, and there was no apparent geographical variation. 
This data showed that most veterinarians servicing the horse industry have to deal with 
this chronic, debilitating problem. Importantly, respondents indicated that the cost of the 
current treatment and management limitations surrounding its use meant that they would 
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be interested in pursuing novel treatment options if they became available. Further, as the 
life-span of domestic horses is increasing, the prevalence of this condition should rise, 
creating more of a need for an alternative therapy. Limitations of online data collection, 
and surveys in particular, are many; however, it is the author’s opinion that the need for 
treatment of this condition is now without question.  
 
The second specific aim of this thesis was to continue the investigation of the underlying 
cellular mechanism of PPID by sequencing the POMC, PC1 and PC2 genes, identifying a 
suitable internal control gene for use in the equine pituitary gland, examining gene 
expression of pro-hormone convertases, and quantifying the differences in POMC, 
ACTH, αMSH and CLIP hormone concentrations in affected and unaffected horses.  Our 
laboratory investigations (Chapter 3) determined that YWHAZ was the best internal 
house-keeping gene for the equine pituitary gland. Comparisons to this gene indicated 
that in horses with PPID, POMC mRNA expression are increased dramatically. 
Additionally, we found that upregulation of PC1 and PC2 also occurs. PC1 and PC2 
upregulation had previously been hypothesized to occur in PPID horses, based on murine 
models lacking the dopamine type-2 receptor (Saiardi 1998). Interestingly, we found a 
similar magnitude of upregulation between the 2 types of pro-hormone convertases, 
which differs from the murine study. This may have been due to the fact that we were 
dealing with horses suffering from a naturally occurring disease versus a genetically 
modified laboratory rodent model or a factor of the method of sample collection. 
Additionally, as the degree, or severity, of PPID varies within and between individuals, it 
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is possible that the low number of horses used in this experiment precluded the ability to 
determine differential upregulation. Irrespective of the cause, the theorized upregulation 
of PC1 and PC2 has now been demonstrated in the horse. Finally, we determined a partial 
sequence for the equine POMC gene as well as for PC1 and PC2. Prior to this, only 
predicted sequences were available in GenBank. The next steps in this research, if we are 
to develop tissue and, or, molecular therapeutic targets for PPID, is to definitively identify 
the ACTH variant responsible for the clinical syndrome. This may allow us to identify 
horses in the prodromal phase of the disease (a definitive antemortem test), leading to 
earlier treatment and prolonging the useful life and welfare of the horse; or to specifically 
target the melanotrophs producing this variant. We know that treatment with a dopamine 
agonist normalizes the circulating levels of ACTH, and the clinical signs of disease 
(Donaldson et al. 2002; Perkins et al. 2002) but other possible medical options exist. 
These include L-deprenyl and BIM-23A760. L-deprenyl is a MOA-B inhibitor which acts 
to prolong the effect of dopamine by reducing breakdown in the synaptic cleft (Bruyette 
et al. 1997). BIM-23A760 is a chimeric compound that has both somatostatin and 
dopamine elements allowing it to bind to both types of receptors (sstr2 and D2R) 
resulting in potent suppression of growth hormone and prolactin in human studies (Colao 
et al. 2011). Local delivery of chemotherapeutic agents such as carboplatin microspheres 
is also a possibility (Chen and Lu 1999). Further, identifying cell-specific markers, such 
as surface epitopes, could allow the development of selective targeting agents to destroy 
the abnormal melanotroph cell-lines. Examples of these include pituitary tumor–derived 
fibroblast growth factor receptor-4 (ptd-FGFR4) and specific-specific variants of human 
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sperm protein 17 (Sp17), which have been shown to be upregulated and expressed on the 
cell-surface of human pituitary tumors (Asa and Ezzat 2005; Grizzi et al. 2012). 
   
The third specific aim of this thesis was to investigate the methodology for site-specific 
application of future therapy for equine PPID; essentially to find a mechanism by which 
future agents could be delivered (Chapters 4, 5, and 6). Imaging the brain is complicated 
in any species as it is surrounded by dense bone. Imaging the equine brain is further 
complicated by the size of the animal, which necessitates modifications to standard 
equipment, or specially designed, and thus expensive, dedicated imaging modalities. 
Options for visualizing the brain include magnetic resonance imaging (MRI) and 
computed tomography (CT). The former is superior in terms of soft tissue interpretation, 
however, access to a 3 Tesla magnet with a bore size big enough for a horse is limited. 
Additionally, the MRI acquisition times are substantially longer than those needed for CT 
imaging. CT is not as good as MRI for the interpretation of soft tissue structures, 
however, by using contrast enhancement the margins of the pituitary gland can be 
delineated when imaged using this methodology (Pease et al. 2011). CT is more widely 
available and thus we elected to develop a highly specific low-volume contrast 
enhancement technique for the equine brain. We reported that the low-volume 
intraarterial administration method was as good at contrast enhancement as the previously 
published high-volume intravenous method and substantially less expensive. The vision 
was that CT, using contrast enhancement, could be used as an adjunctive diagnostic tool, 
in addition to guiding the surgical ablation, or targeted delivery of a melanotroph-specific 
 207 
 
agent to the pars intermedia. Ultimately, however, as our surgical methodology evolved, 
we used standard human interventional radiology techniques. These typically use 
contrast-enhanced fluoroscopy as the standard method of guidance. Fluoroscopy is highly 
versatile. In an equine situation, the portability of the system allows for the unit to be 
moved into the operating room. Many different sizes of patient and positions on the 
surgical table can be accommodated. Different imaging planes can be obtained, with 
newer units having resolution equivalent to CT, and the relatively rapid acquisition times 
and real-time nature of the image allow for accurate placement of instruments within the 
patient. 
 
Given that access to the pituitary gland in the horse will most likely be performed under 
general anesthesia, the effect of general anesthesia on ACTH production was performed. 
Any such changes would have to be taken into account if intra-operative measurements of 
local ACTH concentration are to be used as a marker of the degree of pars intermedia 
ablation, or success of targeted delivery, during surgery (Bons et al 2014). We found that 
ACTH concentration of the blood in the ventral cavernous sinus, and the pulsatility of the 
hormone release, was reduced under general anesthesia.  
 
Finally, 4 surgical methods were attempted in cadavers (heads) and as a terminal 
procedure in live horses, with the intention of accessing the pituitary gland. The 
myeloscopic and trans-sphenopalatine sinus approaches were not successful in our hands 
because of bleeding, and a failure to obtain the correct angle of approach, respectively. 
However, the trans-basisphenoid and minimally invasive trans-venous approach were 
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promising. Without advanced intra-operative guidance in the form of a stereotactic frame 
or a commercial neurosurgical guidance system, the former technique was not as 
repeatable, nor as minimally invasive, as the trans-venous approach to the ventral 
cavernous sinus of the brain. The trans-venous approach fulfilled our aim of gaining 
access to the pituitary gland and is an exciting advance that may allow for the 
development of a technique to effect a long-term cessation of clinical signs of disease, 
and thus improve the welfare of the horse.  
 
7.3 CONCLUSIONS 
In conclusion, we have demonstrated there is a need for an alternative therapy for PPID; 
we continued to build on the understanding of the underlying mechanisms of disease; and 
we developed a repeatable method of accurately delivering the tissue and, or, molecular 
therapeutic agents of the future. 
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APPENDIX A 
 
PAPER AND ONLINE QUESTIONNAIRE CIRCULATED TO DETERMINE 
VETERINARIAN APPROACH TO DIAGNOSIS, MANAGEMENT AND 
REPORTED PREVALENCE 
1. Do you currently have a horse (or horses) in your practice with PPID (equine Cushing's 
disease)? If your answer is "No," please skip to question 11.  
Yes  
No  
 
2. Approximately how many horses do you have with this problem and what percentage 
of your equine patients have this condition ? (2 answers please).  
 
3. What is the approximate mean (average) age of these horses?  
 
4. How was the diagnosis made (in most cases)? Check as many as necessary.  
Clinical signs alone  
Clinical signs and endogenous ACTH concentration  
Clinical signs and a dexamethasone suppression test  
Clinical signs and an ACTH stimulation test  
Clinical signs and combined dexamethasone suppression / TRH stimulation test  
Other (please specify):  
 
5. Are you treating these horses for the primary disease process (pituitary dysfunction or 
pituitary tumor)? If your answer is "No," then please skip to Question 8.  
Yes  
No  
6. Collectively, how are you treating these horses?  
Benign neglect / monitoring  
Medically  
Other (please specify):  
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7. What medical treatments are you using (check all that apply)? Please skip to Question 
11 after completing this question. 
Commercial pergolide mesylate  
Compounded pergolide  
Commercial bromocriptine mesylate  
Commercial trilostane  
Commercial cyproheptadine  
Other (please specify): 
 
 
8. If you are not treating these horses, why not?  
Client limitations  
Drugs not available  
Treatment not warranted  
Other (please specify): 
 
 
9. If client limitations prevent treatment, why?  
Financial limitations  
Management limitations (cannot treat as recommended)  
Other (please specify): 
 
10. If treatment is not warranted, why?  
Age of horse  
Disease not deemed to be of concern (by client or veterinarian)  
Other (please specify): 
 
 
 
11. Do you perceive this disease to be an important equine health issue?  
Yes  
No  
 
Please provide additional comments below if necessary:  
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12. Do you think that we need a new way to treat (or cure) this disease?  
Yes  
No  
 
Please provide additional comments below if necessary:  
 
 
13. Which of the following best describes your practice situation? 
Private practice  
Academia  
Government institution  
Military  
Other (please specify): 
 
14. Which of the following best describes your practice focus? 
Equine only / speciality  
Large animal (equine predominant)  
Large animal (general)  
Small animal / equine  
General mixed practice  
Other (please specify): 
 
15. Please provide your COUNTRY of practice (analysis of prevalence by country will be 
performed) 
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APPENDIX B 
 
LIST OF GENERAL AND EQUINE VETERINARY MEDICAL GROUPS 
PASSING THE SURVEY LINK TO THEIR EMAIL LISTS, POSTED A LINK ON 
THEIR WEB PAGES OR SENDING THE LINK IN NEWSLETTERS. 
 
CVMA-   Canadian Veterinary Medical Association 
OVMA-   Ontario Veterinary Medical Association 
SVMA-   Saskatchewan Veterinary Medical Association 
ABVMA-   Alberta Veterinary Medical Association 
OMVQ-  Ordre des médecins vétérinaires du Québec 
NSVMA-   Nova Scotia Veterinary Medical Association 
AAEP-   American Association of Equine Practitioners 
American Board of Veterinary Practitioners 
American College of Veterinary Internal Medicine- List Server 
European College of Veterinary Internal Medicine- List Server 
Oklahoma Veterinary Medical Association 
BEVA-   British Equine Veterinary Association 
GPM-    German Equine Veterinary Association 
AVEF-   Association Veterinaire Equine Francaise 
AVME (Portugal)-  Associação de Médicos Veterinários de Equinos 
AVEEC-  Associacio de Veterinaris Especialistes en Equids de Catalunya 
 
SIVE-    Società Italiana Veterinari per Equini 
Norwegian Association of Horse Practitioners 
Swedish Equine Veterinary Association 
NZEVA –   New Zealand Equine Veterinary Association 
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AEVA –   Australian Equine Veterinarian Association 
VSBT-   Veterinary Surgeons’ Board of Tasmania 
VSBWA  Veterinary Surgeons’ Board of Western Australia 
SAEVA –   South African Equine Veterinarian Association 
Chilean Association of Equine Veterinarians 
RCVS Charitable Trust 
VetsOnline 
VIN.com 
vetsurgeons.org 
thehorse.com 
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